[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 690
1. Torlakovic E, Lilleby W, Berner A, Torlakovic G, Chibbar R, Furre T, Fosså SD: Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma. Int J Cancer; 2005 Nov 10;117(3):381-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression, distribution and the role of steroid receptors in benign and malignant untreated prostate tissues is well recognized, however, the status of steroid receptors in prostate after radiotherapy (RT) for adenocarcinoma has not yet been studied fully.
  • Significantly higher level of ER-beta expression was found in post-radiation samples of prostate adenocarcinoma and benign epithelium.
  • Tumor AR expression did not change significantly.
  • High levels of pretreatment tumor ER-beta were associated with local recurrence after RT and decreased biochemical recurrence-free survival (p = 0.028).
  • Upregulation of all steroid receptors in the prostate stroma and upregulation of ER-beta in the tumor epithelium after RT, may represent a protective tissue response to radiation-induced tissue injury.
  • Although stromal AR was doubled after RT, the tumor and benign epithelium expression of AR seemed resistant to change by RT.
  • [MeSH-minor] Biopsy, Needle. Cell Line, Tumor. Epithelial Cells / pathology. Humans. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15900599.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Steroid
  •  go-up   go-down


2. Zhang LL, Shao SL, Wu Y: [Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance]. Chin J Cancer; 2010 Jan;29(1):25-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance].
  • BACKGROUND AND OBJECTIVE: Epithelial ovarian cancer involves a number of factors.
  • Recent studies have shown that osteopontin (OPN) is related to the occurrence and development of a variety of tumors, but few studies are on ovarian cancer.
  • B7-H4 is a newly identified tumor marker in ovarian cancer.
  • This study explored the expression of OPN and B7-H4 and their clinical significance in epithelial ovarian tumors.
  • METHODS: The expression of OPN and B7-H4 in 15 cases of normal ovarian tissue, 20 of benign ovarian tumor tissue, 20 of borderline ovarian tumor tissue, and 40 of ovarian cancer tissue were detected by immunohistochemistry, and the relationship of OPN and B7-H4 expression to clinical and pathologic features of ovarian cancer was analyzed.
  • RESULTS: The expression of OPN and B7-H4 were significantly higher in ovarian cancer than in borderline and benign tumors (P<0.05).
  • CONCLUSION: The expression of OPN and B7-H4 increased in epithelial ovarian cancer, which could be referenced in the diagnosis of ovarian malignant tumors.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Osteopontin / metabolism. Ovarian Neoplasms / metabolism. V-Set Domain-Containing T-Cell Activation Inhibitor 1 / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adolescent. Adult. Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038306.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / SPP1 protein, human; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 106441-73-0 / Osteopontin; Ovarian epithelial cancer
  •  go-up   go-down


3. Thyavihally YB, Tongaonkar HB, Desai SB: Benign mixed epithelial stromal tumor of the renal pelvis with exophytic growth: case report. Int Semin Surg Oncol; 2005 Sep 9;2:18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mixed epithelial stromal tumor of the renal pelvis with exophytic growth: case report.
  • BACKGROUND: Mixed epithelial and stromal tumor (MEST) is a distinctive benign composite neoplasm of the kidney predominantly seen in females mostly in the perimenopausal period.
  • Although these tumors are known to arise from renal pelvis, our case was distinct in that it had no intrapelvic component growing in exophytic fashion.
  • Microscopically, the tumor was composed of large collagenized areas containing bundles of spindle cells and several 'microcysts' lined by cuboidal epithelium suggestive of a benign mixed epithelial stromal tumor.
  • DISCUSSION: Mixed epithelial tumors usually present in perimenopausal women as a partially cystic mass.
  • Tumors are composed of irregular mixtures of cystic and solid areas, glands with variable complexity and distribution and the stromal component is characterized by a spindle cell proliferation.
  • Commonly, it arises from the renal parenchyma and pelvis and nephrectomy is advocated to manage these tumors.
  • CONCLUSION: MEST is a distinctive benign tumor of the kidney that should be distinguished from other renal neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2004 Dec;5(12):747-9 [15581546.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):958-70 [10895818.001]
  • [Cites] Hum Pathol. 2001 May;32(5):513-20 [11381370.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):700-2 [11764393.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):2-20 [9503503.001]
  • [Cites] Hinyokika Kiyo. 2004 Jan;50(1):49-52 [15032017.001]
  • [Cites] Pathologe. 2004 Sep;25(5):356-61 [15127227.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):359-67 [15322873.001]
  • [Cites] Pathol Res Pract. 1998;194(6):445-8 [9689654.001]
  • [Cites] Adv Anat Pathol. 2003 Jul;10(4):223-33 [12826829.001]
  • (PMID = 16150156.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1215508
  •  go-up   go-down


Advertisement
4. Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, Gazdar AF, Schorge JO: Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res; 2005 Aug 1;11(15):5365-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation profile of ovarian epithelial neoplasms.
  • PURPOSE: Ovarian carcinomas are believed to arise de novo from surface epithelium, but the actual molecular pathogenesis is unknown.
  • The aim of this study was to compare the promoter hypermethylation profiles of ovarian epithelial neoplasms to better understand the role of epigenetic silencing in carcinogenesis.
  • EXPERIMENTAL DESIGN: We analyzed the DNA promoter methylation status of eight tumor suppressor and cancer-related genes (p16, RARbeta, E-cadherin,H-cadherin, APC, GSTP1, MGMT, RASSF1A) in 23 benign cystadenomas, 23 low malignant potential (LMP) tumors, and 23 invasive carcinomas by methylation-specific PCR.
  • RESULTS: Benign cystadenomas exhibited promoter hypermethylation in only two genes, p16 (13%) and E-cadherin (13%).
  • LMP tumors also showed p16 (22%) and E-cadherin (17%) methylation, in addition to RARbeta (9%) and H-cadherin (4%).
  • The mean methylation index was highest in invasive tumors [0.20 versus 0.065 (LMP) and 0.033 (cystadenomas); P = 0.001].
  • Three genes exhibited higher methylation frequencies in invasive tumors: RASSF1A (30% versus 0%; P = 0.0002), H-cadherin (22% versus 2%; P = 0.013), and APC (22% versus 0%; P = 0.003).
  • CONCLUSIONS: Promoter hypermethylation is a frequent epigenetic event that occurs most commonly in invasive epithelial ovarian carcinomas.
  • The profile of aberrant methylation suggests that an accumulation of events at specific genes may trigger malignant transformation of some benign cystadenomas and LMP tumors.
  • [MeSH-major] DNA Methylation. Neoplasms, Glandular and Epithelial / genetics. Ovarian Neoplasms / genetics. Promoter Regions, Genetic
  • [MeSH-minor] Adenomatous Polyposis Coli Protein / genetics. Adult. Aged. Aged, 80 and over. Cadherins / genetics. Carcinoma / genetics. Carcinoma / pathology. Cell Transformation, Neoplastic. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Cystadenoma / genetics. DNA / metabolism. Epigenesis, Genetic. Female. Gene Silencing. Glutathione S-Transferase pi / genetics. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. O(6)-Methylguanine-DNA Methyltransferase / genetics. Polymerase Chain Reaction. Receptors, Retinoic Acid / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061849.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Cadherins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / H-cadherin; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta; 9007-49-2 / DNA; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


5. Faitaroni LA, Bueno MR, De Carvalhosa AA, Bruehmueller Ale KA, Estrela C: Ameloblastoma suggesting large apical periodontitis. J Endod; 2008 Feb;34(2):216-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This case report describes the endodontic treatment of a large apical periodontitis with well-defined margins adjacent to teeth #22-24.
  • Ameloblastoma is a benign epithelial neoplasm of odontogenic origin, and depending on the stage of development, it can mimic a periapical lesion and therefore should be considered in establishing an endodontic differential diagnosis.
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Follow-Up Studies. Humans. Male. Mandibular Diseases / diagnosis. Middle Aged. Root Canal Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18215686.001).
  • [ISSN] 0099-2399
  • [Journal-full-title] Journal of endodontics
  • [ISO-abbreviation] J Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Moslemi MK: Mixed epithelial and stromal tumor of the kidney or adult mesoblastic nephroma: an update. Urol J; 2010;7(3):141-7
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for mesoblastic nephroma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed epithelial and stromal tumor of the kidney or adult mesoblastic nephroma: an update.
  • PURPOSE: Our aim was to review the spectrum of usual and unusual clinical and morphologic findings observed in mixed epithelial and stromal tumor of the kidney (MEST).
  • RESULTS: Mixed epithelial and stromal tumor is a relatively rare and distinct neoplasm of the kidney that should be distinguished from other renal neoplasms.
  • Although the overall prognosis is favorable, recurrence and malignant transformation of MEST can occur CONCLUSION: It is difficult to distinguish benign or malignant nature on imaging studies.


7. Mukherjee S, Frolova N, Sadlonova A, Novak Z, Steg A, Page GP, Welch DR, Lobo-Ruppert SM, Ruppert JM, Johnson MR, Frost AR: Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther; 2006 Jun;5(6):674-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer.
  • The hedgehog pathway regulates epithelial-mesenchymal interactions, differentiation, proliferation and survival during development.
  • Using real-time, quantitative PCR, laser capture microdissection, and immunohistochemistry, distinctive patterns of expression of the hedgehog pathway members patched 1 (PTCH1), smoothened, GLI1, GLI2 and the 3 hedgehog ligands were identified for epithelial cells and stromal fibroblasts in benign breast and breast cancer.
  • Hedgehog ligands were expressed at higher levels in some cancer epithelial cell lines compared to noncancerous epithelial cells.
  • Correspondingly, expression of GLI1, a transcription factor and transcriptional product of hedgehog signaling, was increased 8-fold in cancer epithelial cell lines; however, PTCH1, also a transcriptional target of hedgehog signaling in many cell types, was not increased.
  • Hedgehog-mediated transcription, as indicated by a reporter of GLI-dependent promoter activity and by expression of GLI1 transcripts, was reduced by the hedgehog pathway inhibitor cyclopamine in both MDA-MB-435 cancer epithelial cells and MCF10AT epithelial cells, a cell line derived from benign breast.
  • However, cyclopamine reduced viability of cancer epithelial cell lines, including MDA-MB-435, but did not specifically affect fibroblasts or epithelial cells from benign breast, including MCF10AT.
  • These results demonstrate modulation of GLI-mediated transcription in both cancer and benign-derived epithelial cells by cyclopamine and sonic hedgehog, and further suggest that hedgehog signaling contributes to the survival of only the cancer epithelial cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2002 Apr;17(2):623-37 [11962762.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6 [16488983.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):923-8 [12615704.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):508-13 [12652302.001]
  • [Cites] J Endocrinol. 2003 Sep;178(3):467-78 [12967338.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):313-20 [14733907.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):353-62 [14611647.001]
  • [Cites] J Agric Food Chem. 2004 May 19;52(10):2832-9 [15137822.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3479-85 [15150101.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2577-85 [15277480.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):165-81 [15300011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] Development. 2004 Oct;131(20):5009-19 [15371305.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Int J Mol Med. 2004 Nov;14(5):793-9 [15492847.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):711-3 [10505029.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:29 [15482598.001]
  • [Cites] Breast Cancer Res. 2005;7(1):R46-59 [15642169.001]
  • [Cites] Development. 1999 Nov;126(22):5181-93 [10529434.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):236-43 [10981877.001]
  • [Cites] Nature. 2001 Feb 1;409(6820):633-7 [11214324.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] J Invest Dermatol. 2001 Mar;116(3):472-4 [11231326.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):97-104 [11322829.001]
  • [Cites] Dev Biol. 2001 Oct 1;238(1):133-44 [11783999.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):118-27 [11857395.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):599-621 [11962761.001]
  • [Cites] Dev Biol. 2005 Apr 1;280(1):111-21 [15766752.001]
  • [Cites] Genomics. 2005 Apr;85(4):462-71 [15780749.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17 [15803137.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Development. 2005 Jul;132(14):3267-79 [15983404.001]
  • [Cites] J Neurosci. 2005 Sep 7;25(36):8338-46 [16148242.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1698-705 [15905200.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):139-48 [16003737.001]
  • [Cites] Hum Mol Genet. 2005 Nov 15;14(22):3379-88 [16203740.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):107-15 [12241103.001]
  • (PMID = 16855373.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA091421; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / R01 CA087728; United States / NCI NIH HHS / CA / R03 CA105950
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Hedgehog Proteins; 0 / RNA, Neoplasm; 0 / SHH protein, human; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ NIHMS11622; NLM/ PMC1557635
  •  go-up   go-down


8. Richter M, Meyer W, Küster J, Middel P: Exophytic benign mixed epithelial stromal tumour of the kidney: case report of a rare tumour entity. Diagn Pathol; 2010;5:16
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exophytic benign mixed epithelial stromal tumour of the kidney: case report of a rare tumour entity.
  • BACKGROUND: Mixed epithelial and stromal tumour (MEST) represents a recently described benign composite neoplasm of the kidney, which predominantly affects perimenopausal females.
  • Most tumours are benign, although rare malignant cases have been observed.
  • Surgical exploration showed a tumour arising from the lower anterior hilus of the left kidney.
  • The tumour could be excised by preserving the kidney.
  • By intraoperative frozen section the tumour showed characteristic features of MEST with epithelial-covered cysts embedded in an "ovarian-like" stroma.
  • Additional immunohistochemistry investigations showed expression for hormone receptors by the stromal component of the tumour.
  • Commonly, the tumour arises from the renal parenchyma or pelvis.
  • The tumour is composed of an admixture of cystic and sometimes more solid areas.
  • CONCLUSION: MEST represents a distinctive benign tumour entity of the kidney, which affects perimenopausal woman.
  • The tumour should be distinguished from other cystic renal neoplasms.
  • By imaging studies it is difficult to distinguish between a benign or malignant nature of the tumour.
  • [MeSH-major] Epithelial Cells / pathology. Kidney Neoplasms / pathology. Mixed Tumor, Malignant / pathology. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ultrastruct Pathol. 2005 May-Aug;29(3-4):283-6 [16036882.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):747-9 [15581546.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):489-500 [17414095.001]
  • [Cites] Pathology. 2007 Apr;39(2):235-40 [17454754.001]
  • [Cites] Mod Pathol. 2008 Jan;21(1):60-5 [17873894.001]
  • [Cites] Urology. 2008 Jun;71(6):1142-8 [18313107.001]
  • [Cites] Eur Urol. 2008 Dec;54(6):1237-46 [18006141.001]
  • [Cites] Eur Urol. 2008 Dec;54(6):1245-6 [18006142.001]
  • [Cites] Am J Surg Pathol. 2009 Jan;33(1):72-80 [18971776.001]
  • [Cites] APMIS. 2008 Nov;116(11):1013-5 [19133001.001]
  • [Cites] Pathology. 2009;41(4):403-6 [19404861.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):958-70 [10895818.001]
  • [Cites] J Urol. 2001 Oct;166(4):1381-2 [11547080.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):700-2 [11764393.001]
  • [Cites] Histopathology. 2004 Mar;44(3):302-4 [14987239.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):359-67 [15322873.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):2-20 [9503503.001]
  • [Cites] Pathol Res Pract. 1998;194(6):445-8 [9689654.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jan;130(1):80-5 [16390243.001]
  • (PMID = 20193076.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2842239
  • [General-notes] NLM/ Original DateCompleted: 20100609
  •  go-up   go-down


9. Weyers W, Hörster S, Diaz-Cascajo C: Tumor of follicular infundibulum is Basal cell carcinoma. Am J Dermatopathol; 2009 Oct;31(7):634-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor of follicular infundibulum is Basal cell carcinoma.
  • Tumor of follicular infundibulum (TFI) is currently thought to be a benign epithelial neoplasm with follicular differentiation.
  • We reexamined 24 cases of TFI and noted, often only focally, many changes typical of BCC, including palisading of cells at the periphery of aggregations, germinative cells, follicular germs in the absence of a follicular papilla, crowding of cells, individual necrotic neoplastic cells, fibromucinous stroma, and clefts between aggregations of neoplastic cells and stroma.
  • [MeSH-major] Carcinoma, Basal Cell / classification. Carcinoma, Basal Cell / pathology. Skin Neoplasms / classification. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652582.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Hori S, Nara S, Shimada K, Ojima H, Kanai Y, Hiraoka N: Serous cystic neoplasm in an intrapancreatic accessory spleen. Pathol Int; 2010 Oct;60(10):681-4
MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous cystic neoplasm in an intrapancreatic accessory spleen.
  • Serous cystic neoplasm (SCN) of the pancreas is a benign epithelial neoplasm, except in extremely rare malignant cases.
  • Pathologically the 25-mm solid mass was an IPAS showing proliferation of clear cuboidal tumor cells without atypia, forming numerous small cysts.
  • The tumor cells were rich in cytoplasmic glycogen and distributed in the splenic tissue almost diffusely.
  • Immunohistochemically, tumor cells were positive for cytokeratins, MUC6, and neuron-specific enolase, and negative for neuroendocrine markers.
  • This tumor is suggested to develop as a VHL-associated SCN from coexisting pancreatic tissue in IPAS rather than as a metastatic tumor.
  • [MeSH-major] Choristoma / pathology. Cystadenoma, Serous / pathology. Pancreatic Diseases / pathology. Spleen. von Hippel-Lindau Disease / pathology

  • Genetic Alliance. consumer health - Spleen neoplasm.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Pathology International © 2010 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd.
  • [ErratumIn] Pathol Int. 2010 Dec;60(12):798
  • (PMID = 20846266.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


11. Eggers G, Eggers H, Sander N, Kössling F, Chilla R: Histological features and malignant transformation of inverted papilloma. Eur Arch Otorhinolaryngol; 2005 Apr;262(4):263-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inverted papilloma (IP) is a primarily benign epithelial neoplasm with a propensity to transform to squamous cell carcinoma (SCC).
  • Thirteen patients had suffered a recurrence of a previously treated IP.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Neoplasm Recurrence, Local / pathology. Nose Neoplasms / pathology. Papilloma, Inverted / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1992 Sep;102(9):973-6 [1325585.001]
  • [Cites] Laryngoscope. 1992 Mar;102(3):231-6 [1545648.001]
  • [Cites] Am J Otolaryngol. 1989 Jul-Aug;10(4):273-81 [2764240.001]
  • [Cites] Laryngol Rhinol Otol (Stuttg). 1984 Jul;63(7):347-52 [6482611.001]
  • [Cites] Adv Anat Pathol. 2001 Mar;8(2):53-64 [11236954.001]
  • [Cites] Laryngoscope. 2002 Aug;112(8 Pt 1):1372-7 [12172247.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1971 Feb;80(1):78-82 [5541886.001]
  • [Cites] Laryngoscope. 1999 Jan;109(1):21-6 [9917034.001]
  • [Cites] Laryngoscope. 1995 Jan;105(1):66-71 [7837916.001]
  • [Cites] Arch Dermatol. 1968 Dec;98(6):636-9 [5697234.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1971 Apr;80(2):192-206 [4323842.001]
  • [Cites] Cancer. 1972 Sep;30(3):668-90 [5075353.001]
  • [Cites] Laryngoscope. 1991 Oct;101(10):1094-101 [1921638.001]
  • [Cites] Laryngoscope. 1995 Jan;105(1):72-9 [7837917.001]
  • [Cites] Laryngoscope. 2001 Aug;111(8):1395-400 [11568575.001]
  • [Cites] HNO. 1987 Apr;35(4):167-71 [3583837.001]
  • [Cites] Hum Pathol. 1986 Apr;17(4):393-400 [3957337.001]
  • [Cites] Laryngoscope. 1995 Mar;105(3 Pt 1):282-8 [7877417.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Nov;113(5):558-63 [7478645.001]
  • [Cites] Arch Otolaryngol. 1965 Sep;82:296-300 [14327033.001]
  • [Cites] HNO. 1994 Nov;42(11):670-6 [7843998.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Jul;113(1):49-55 [7603721.001]
  • [Cites] Arch Otolaryngol. 1980 Dec;106(12):767-71 [7436854.001]
  • [Cites] Cancer Res. 1986 Apr;46(4 Pt 2):2185-8 [3004723.001]
  • [Cites] Laryngoscope. 1980 Jan;90(1):53-60 [7356770.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1320-8 [9083153.001]
  • [Cites] Laryngoscope. 1989 Nov;99(11):1117-24 [2682100.001]
  • [Cites] Laryngoscope. 1995 Feb;105(2):178-83 [8544600.001]
  • (PMID = 15258811.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Bhalla RK, Wright ED: Predicting the site of attachment of sinonasal inverted papilloma. Rhinology; 2009 Dec;47(4):345-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STATEMENT OF PROBLEM: Sinonasal inverted papilloma is a benign, epithelial neoplasm, which has a propensity for malignant transformation and recurrence.
  • The evolution of endoscopic trans-nasal surgery has facilitated less destructive and, more functionally and cosmetically acceptable approaches to this tumour.
  • Precise surgery is enhanced by pre-operative localisation of the site of tumour attachment.
  • Intra-operatively, the actual site of tumour attachment was established.
  • A correlation between the predicted and actual site of tumour attachment was calculated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936356.001).
  • [ISSN] 0300-0729
  • [Journal-full-title] Rhinology
  • [ISO-abbreviation] Rhinology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


13. Furusato B, Shaheduzzaman S, Petrovics G, Dobi A, Seifert M, Ravindranath L, Nau ME, Werner T, Vahey M, McLeod DG, Srivastava S, Sesterhenn IA: Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens. Prostate Cancer Prostatic Dis; 2008;11(2):194-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens.
  • Furthermore, to increase the sample quality, we utilized laser capture microdissection of prostate tumor and benign epithelial cells.
  • [MeSH-major] Adenocarcinoma / genetics. Epithelial Cells / metabolism. Gene Expression Profiling. Neoplasm Proteins / genetics. Prostate / metabolism. Prostatic Neoplasms / genetics. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Tissue Preservation / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768422.001).
  • [ISSN] 1476-5608
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


14. Zhao SJ, Liu JY, Ren FR, Feng YJ: [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm]. Zhonghua Fu Chan Ke Za Zhi; 2005 Apr;40(4):264-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm].
  • OBJECTIVE: To study the expression of glucose transporter-1 (GLUT1) and its correlation with basic fibroblast growth factor (bFGF) and proliferating cell nuclear antigen (PCNA) in epithelial ovarian neoplasm.
  • METHODS: Streptavidin-peroxidase complex technique was used to examine the expression of GLUT1, bFGF and PCNA protein in six cases of normal ovarian tissue, 20 cases of benign epithelial tumors, seven cases of borderline tumor and 44 cases of epithelial ovarian carcinoma.
  • RESULTS: In normal ovary and benign ovarian tumor, GLUT1 was not detected, but in borderline ovarian tumor and cancer, the positive expression ratio of GLUT1 was 6/7 and 91% (40/44), respectively.
  • The intensity of GLUT1 in ovarian epithelial neoplasm was significantly higher than in borderline tumors.
  • The staining intensity of GLUT1 was significantly correlated with the histological grade of the tumor (r(S) = 0.499, P = 0.001), and was positively correlated with the clinical stage, cancer invasion and lymph node metastasis.
  • bFGF positive rate in tumor was 57% (25/44).
  • CONCLUSIONS:. (1) The expression of GLUT1 may be closely related to malignant transformation of ovarian epithelial tumors.
  • Both of them play important roles in the carcinogenesis and progression of ovarian epithelial carcinoma.
  • [MeSH-major] Epithelium / metabolism. Fibroblast Growth Factor 2 / metabolism. Glucose Transporter Type 1 / genetics. Ovarian Neoplasms / genetics. Ovarian Neoplasms / metabolism. Proliferating Cell Nuclear Antigen / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15924676.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Proliferating Cell Nuclear Antigen; 0 / SLC2A1 protein, human; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


15. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, Moon WS: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology; 2009;41(4):366-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic significance of SIRT1 in ovarian epithelial tumours.
  • Therefore, we investigated the prevalence and the prognostic impact of SIRT1 and p53 expression in ovarian epithelial tumours.
  • METHODS: Immunohistochemical expression of SIRT1 and p53 were evaluated using tissue microarray in 40 cases of benign epithelial tumours, 36 cases of borderline tumours, and 90 cases of malignant tumours.
  • RESULTS: Expression of SIRT1 was significantly increased in malignant epithelial tumours compared to benign and borderline epithelial tumours (p < 0.001).
  • Despite the frequent expression of SIRT1 in malignant ovarian epithelial tumours, serous carcinomas of high FIGO stage showed less frequent SIRT1 expression compared to that of low stage serous carcinomas (p = 0.029).
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Sirtuins / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. Sirtuin 1. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404850.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
  •  go-up   go-down


16. Han HS, Min SK, Lee HK, Kim SW, Park YH: Laparoscopic distal pancreatectomy with preservation of the spleen and splenic vessels for benign pancreas neoplasm. Surg Endosc; 2005 Oct;19(10):1367-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic distal pancreatectomy with preservation of the spleen and splenic vessels for benign pancreas neoplasm.
  • BACKGROUND: Laparoscopic distal pancreatectomy to conserve the spleen is a beneficial operation for patients with benign and borderline malignancy in the pancreas.
  • METHODS: From May 2000 to July 2003, five laparoscopic distal pancreatectomies with preservation of the spleen and splenic vessels were performed for benign pancreas neoplasm at Ewha Womans University Mokdong Hospital in Seoul, Korea.
  • RESULTS: The postoperative pathologic diagnoses were two serous cystadenomas, two mucinous cystadenomas, and one solid and papillary epithelial tumor.
  • The tumors ranged in size from 1.5 to 7 cm.
  • CONCLUSION: Laparoscopic distal pancreatectomy with preservation of the spleen and splenic vessels is a relatively safe and feasible option for the management of benign tumor or borderline malignancy in the distal pancreas.

  • Genetic Alliance. consumer health - Spleen neoplasm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Laparosc Endosc Percutan Tech. 1999 Aug;9(4):290-3 [10871180.001]
  • [Cites] Surgery. 1996 Dec;120(6):1051-4 [8957494.001]
  • [Cites] Surg Endosc. 2004 Mar;18(3):402-6 [14735345.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):154-64 [10398903.001]
  • [Cites] Arch Surg. 1988 May;123(5):550-3 [3358679.001]
  • [Cites] Surg Endosc. 2002 Sep;16(9):1358-61 [11984672.001]
  • [Cites] Surg Endosc. 1999 Jan;13(1):26-9 [9869683.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):996-1003 [12163971.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):217-8 [11961650.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):164-8 [11822953.001]
  • [Cites] J Am Coll Surg. 2001 Sep;193(3):281-7 [11548798.001]
  • [Cites] Acta Chir Hung. 1997;36(1-4):359-61 [9408401.001]
  • [Cites] Surg Endosc. 2001 Jul;15(7):759 [11591991.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):149-58 [12170019.001]
  • [Cites] Am J Surg. 1996 Oct;172(4):320-3 [8873521.001]
  • [Cites] Surg Endosc. 1994 Jan;8(1):57-60; discussion 60-1 [8153866.001]
  • (PMID = 16193376.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


17. Guo RX, Qiao YH, Zhou Y, Li LX, Shi HR, Chen KS: Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Int; 2008 Dec;58(12):749-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer.
  • AKT plays an important role in malignant behavior of tumors.
  • The purpose of the present study was to determine the expression of phosphorylated AKT (P-AKT) and nuclear factor-kappaB (NF-kappaB) p65 and their association with clinicopathological parameters and prognosis in epithelial ovarian tumor.
  • On immunohistochemistry 115 samples of ovarian tissue that included 68 specimens of epithelial ovarian cancer, 12 of borderline tumor, 24 of epithelial benign tumor and 11 of normal ovary, were evaluated.
  • The positive expression rate of P-AKT and NF-kappaB p65 were higher in epithelial ovarian cancer than in normal ovarian tissue (P<0.01).
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Phosphorylation. Prognosis. Survival Rate. Up-Regulation. Young Adult


18. Räsänen K, Vaheri A: TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes. J Dermatol Sci; 2010 May;58(2):97-104
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes.
  • BACKGROUND: Transforming growth factor beta (TGF-beta) acts as a tumor promoter by inducing epithelial-mesenchymal transition (EMT), which leads to a motile phenotype, enabling invasion and metastasis of cancer cells.
  • Cancer-related inflammation, mediated by prostaglandins, has been proposed as a critical mechanism in conversion of benign cells to malignant.
  • OBJECTIVE: Induction of cyclooxygenase 2 (COX-2), producer of prostaglandins, is thought to be a prerequisite for TGF-beta-induced EMT in benign cells.
  • RESULTS: TGF-beta1 caused proliferation arrest of benign and malignant HaCaT cells, and changed the epithelial morphology of benign and low-grade malignant cells, but not metastatic cells, to mesenchymal spindle-shape.
  • Epithelial junction proteins ZO-1 and E-cadherin were downregulated in all cell lines in response to TGF-beta1, but mesenchymal markers were not induced, suggesting a partial EMT response.
  • COX-2 and migration were induced only in benign HaCaT derivatives.
  • Malignant derivatives did not induce COX-2 in response to TGF-beta 1 treatment, thus emphasizing the role of inflammation in EMT response of benign cells.
  • CONCLUSIONS: TGF-beta1 operates via distinct mechanisms in inducing EMT and metastasis, and supporting this we show that TGF-beta1 induces COX-2 and promotes the migration of benign cells, but does not further augment the migration of malignant cells, indicating their resistance to TGF-beta1 in the context of motility.
  • [MeSH-major] Epithelium / metabolism. Gene Expression Regulation, Neoplastic. Keratinocytes / metabolism. Mesoderm / metabolism. Transforming Growth Factor beta1 / physiology
  • [MeSH-minor] Cell Line, Tumor. Cell Movement. Cell Proliferation. Chemotaxis. Humans. Immunohistochemistry / methods. Models, Biological. Neoplasm Metastasis. Transforming Growth Factor beta / metabolism. Wound Healing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20399617.001).
  • [ISSN] 1873-569X
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


19. Zhang SL, Yu Y, Jiang T, Lin B, Gao H: [Expression and significance of KiSS-1 and its receptor GPR54 mRNA in epithelial ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi; 2005 Oct;40(10):689-92
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of KiSS-1 and its receptor GPR54 mRNA in epithelial ovarian cancer].
  • OBJECTIVE: To study the expression and significance of metastasis suppressor gene KiSS-1 and its receptor GPR54 in epithelial ovarian cancer.
  • METHOD: The expression and their clinical significance of KiSS-1 and GPR54 were evaluated by RT-PCR in 37 patients with epithelial ovarian cancer, 15 patients with borderline epithelial ovarian tumors, 15 patients with epithelial benign tumors and 11 patients with normal ovarian tissues.
  • RESULTS: The positivity and relative contents of KiSS-1 mRNA in patients with epithelial ovarian cancer (68%, 0.82 +/- 0.09) and borderline epithelial ovarian tumors (60%, 0.80 +/- 0.10) were all higher than in patients with epithelial benign tumor (20%, 0.65 +/- 0.10) and normal ovarian tissues (18%, 0.66 +/- 0.06; P < 0.05).
  • The positivity and relative contents of KiSS-1 mRNA in patients with epithelial ovarian cancer correlated with their clinical stage and lymph node metastasis (P < 0.05).
  • There was no difference in the positivity and relative contents of GPR54 mRNA between patients with epithelial ovarian cancer (70%, 0.79 +/- 0.07), borderline epithelial ovarian tumor (67%, 0.76 +/- 0.10), benign epithelial ovarian tumor (60%, 0.73 +/- 0.07) and normal ovarian tissues (45%, 0.78 +/- 0.08), respectively (all P > 0.05).
  • The positivity and relative contents of GPR54 mRNA in patients with epithelial ovarian cancer did not correlate with their clinical stage, histology grade, lymph node metastasis and production of ascites (P > 0.05).
  • CONCLUSION: KiSS-1 and GPR54 may play an important role in inhibiting the invasion and metastasis of early epithelial ovarian cancer.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / pathology. Receptors, G-Protein-Coupled / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Female. Humans. Kisspeptins. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277902.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / KISS1 protein, human; 0 / KISS1R protein, human; 0 / Kisspeptins; 0 / RNA, Messenger; 0 / Receptors, G-Protein-Coupled; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


20. Ungari C, Paparo F, Colangeli W, Iannetti G: Parotid glands tumours: overview of a 10-year experience with 282 patients, focusing on 231 benign epithelial neoplasms. Eur Rev Med Pharmacol Sci; 2008 Sep-Oct;12(5):321-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid glands tumours: overview of a 10-year experience with 282 patients, focusing on 231 benign epithelial neoplasms.
  • Salivary gland tumours are uncommon, representing less than 6% of head and neck neoplasm.
  • Pleomorphic adenoma is the most common benign epithelial salivary gland neoplasm, comprising 50%-74% of all parotid tumours.
  • It is followed by Warthin's tumour (4-14%).
  • The authors retrospectively reviewed 282 eligible patients surgically treated for parotid gland tumours in the last 10 years, focusing on 231 benign epithelial neoplasms.
  • The diagnosis of a parotid gland neoplasm must be considered in any patient presenting with a lump near the mandible.
  • Smoking habit is important in Warthin's tumour pathogenesis.
  • Tumour pseudopodia and capsule ruptures are recognised factors involved in pleomorphic adenoma recurrences but also tumour multicentricity might play an important role.
  • [MeSH-major] Epithelium / surgery. Parotid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024217.001).
  • [ISSN] 1128-3602
  • [Journal-full-title] European review for medical and pharmacological sciences
  • [ISO-abbreviation] Eur Rev Med Pharmacol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


21. Augustin T, Vandermeer TJ: Intraductal papillary mucinous neoplasm: a clinicopathologic review. Surg Clin North Am; 2010 Apr;90(2):377-98

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm: a clinicopathologic review.
  • Intraductal papillary mucinous neoplasm (IPMN) is an intraductal mucin-producing epithelial neoplasm that arises from the main pancreatic duct (MD-IPMN), secondary branch ducts (BD-IPMN), or both (mixed type; Mix-IPMN).
  • Neoplastic progression from benign adenoma to invasive adenocarcinoma has not been proven but is generally thought to occur.
  • With increasing recognition of IPMN, our understanding of the diagnosis and management of the tumors is evolving.
  • [MeSH-minor] Algorithms. Biopsy, Fine-Needle / methods. Cholangiopancreatography, Endoscopic Retrograde. Diagnostic Imaging. Dilatation, Pathologic. Disease Progression. Endosonography. Epithelium / pathology. Humans. Mucins / metabolism. Neoplasm Invasiveness. Pancreatic Ducts / pathology. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20362793.001).
  • [ISSN] 1558-3171
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  • [Number-of-references] 96
  •  go-up   go-down


22. Sakurai H, Kaji M, Mukai K, Suemasu K: Ectopic hamartomatous thymoma--a truly rare neoplasm: report of a case. Surg Today; 2010;40(2):146-9
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic hamartomatous thymoma--a truly rare neoplasm: report of a case.
  • An ectopic hamartomatous thymoma is an extremely rare benign neoplasm that commonly occurs in the lower neck region.
  • It has distinctive pathological features that include haphazardly arranged spindle cells, epithelial cells, and mature fat tissue.
  • This report presents a case of a 26-year-old man with ectopic hamartomatous thymoma in the left supraclavicular region, and discusses the current knowledge regarding this type of lesion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1990 Jun;21(6):662-8 [1693594.001]
  • [Cites] Histopathology. 2004 Aug;45(2):202-4 [15279645.001]
  • [Cites] Histopathology. 1990 Dec;17(6):572-4 [2076891.001]
  • [Cites] Indian J Cancer. 1993 Dec;30(4):192-5 [8206502.001]
  • [Cites] APMIS. 2002 Aug;110(7-8):565-70 [12390415.001]
  • [Cites] Surg Today. 2008;38(4):300-4 [18368317.001]
  • [Cites] Arch Pathol Lab Med. 2003 Sep;127(9):e378-81 [12946212.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1360-70 [15371953.001]
  • [Cites] Am J Surg Pathol. 1984 Jul;8(7):501-13 [6742312.001]
  • [Cites] J Laryngol Otol. 1993 Feb;107(2):155-8 [8496655.001]
  • [Cites] Eur J Surg. 1998 Aug;164(8):629-30 [9720942.001]
  • [Cites] Head Neck. 2002 Aug;24(8):800-4 [12203807.001]
  • [Cites] Scand J Plast Reconstr Surg Hand Surg. 2006;40(4):249-52 [16912001.001]
  • [Cites] Virchows Arch. 2000 Dec;437(6):643-7 [11193476.001]
  • [Cites] Hum Pathol. 2007 Jul;38(7):1092-5 [17574947.001]
  • [Cites] Acta Cytol. 2007 Jul-Aug;51(4):672-5 [17718153.001]
  • [Cites] J Cutan Pathol. 2006 May;33(5):369-72 [16640545.001]
  • [Cites] Histopathology. 1996 Dec;29(6):549-55 [8971562.001]
  • [Cites] Pathology. 2000 May;32(2):142-6 [10840837.001]
  • [Cites] Acta Cytol. 1999 Mar-Apr;43(2):232-4 [10097715.001]
  • (PMID = 20107954.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Satoh K, Hamada S, Kanno A, Hirota M, Umino J, Ito H, Masamune A, Egawa S, Unno M, Shimosegawa T: Expression of MSX2 predicts malignancy of branch duct intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol; 2010 Jul;45(7):763-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MSX2 predicts malignancy of branch duct intraductal papillary mucinous neoplasm of the pancreas.
  • BACKGROUND: To distinguish malignant from benign branch duct (BD)-intraductal papillary mucinous neoplasm (IPMN) still remains difficult.
  • The aim of this study was to assess the involvement of MSX2 in IPMN development and whether its expression would differentiate malignant from benign IPMN.
  • The role of MSX2 in the pancreatic duct cell was assessed by the induced expression of MSX2 in a normal human pancreatic duct epithelial cell line (HPDE).
  • RESULTS: Malignant IPMN expressed significantly higher levels of MSX2 mRNA than benign IPMN lesions.
  • MSX2 protein expression was frequently found in borderline and malignant lesions (20/29, 68.9%), while its expression was seen in only one of 16 benign IPMN tissues.
  • CONCLUSIONS: Based on our results, MSX2 plays a pivotal role in the development of IPMN through growth stimulation of tumor cells, and its expression was identified as an independent predictive factor for malignancy of BD-IPMN.
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Aged. Cell Line. Cell Proliferation. Epithelial Cells / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Multivariate Analysis. Pancreatic Ducts / cytology. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology. Predictive Value of Tests. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):117-22 [14716244.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4222-6 [9766641.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2269-75 [16331618.001]
  • [Cites] Dev Biol. 1999 Jan 15;205(2):260-74 [9917362.001]
  • [Cites] Oncol Rep. 2008 May;19(5):1185-90 [18425375.001]
  • [Cites] Am J Pathol. 2008 Apr;172(4):926-39 [18349132.001]
  • [Cites] Gastrointest Endosc. 1998 Aug;48(2):164-71 [9717782.001]
  • [Cites] Oncogene. 2001 Apr 19;20(17):2153-60 [11360199.001]
  • [Cites] J Gastrointest Surg. 2002 Sep-Oct;6(5):662-3 [12399053.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2009-15 [9951855.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7482-6 [1977161.001]
  • [Cites] Arch Surg. 1999 Oct;134(10 ):1131-6 [10522860.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):195-205 [15300013.001]
  • [Cites] Pancreas. 1996 May;12(4):362-8 [8740403.001]
  • [Cites] Development. 1996 Sep;122(9):2729-37 [8787747.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):12-8; discussion 18-9 [12559180.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):768-74 [17516553.001]
  • [Cites] Arch Surg. 2002 Nov;137(11):1274-8 [12413317.001]
  • [Cites] Dev Biol. 1999 May 15;209(2):298-307 [10328922.001]
  • [Cites] Nature. 1991 Aug 1;352(6334):429-31 [1677742.001]
  • [Cites] Surgery. 2002 Jul;132(1):80-5 [12110799.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):261-5 [12590239.001]
  • [Cites] Int J Pancreatol. 1993 Oct;14(2):135-43 [8283077.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):271-8 [11466679.001]
  • [Cites] Gastroenterology. 1996 Jun;110(6):1909-18 [8964418.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Sep;20(9):1379-84 [16105124.001]
  • [Cites] Oncogene. 2007 Nov 29;26(54):7526-34 [17546050.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1759-64 [17686073.001]
  • [Cites] J Pathol. 2006 Sep;210(1):42-8 [16794990.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):51-6 [8099533.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):419-29 [11159180.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Jul 15;194(1):187-93 [7687426.001]
  • [Cites] Mod Pathol. 2007 Dec;20(12):1238-44 [17906614.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Nov;18(11):1323-4 [14535994.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2007 Sep;104(9):1338-43 [17827904.001]
  • [Cites] Am J Pathol. 1996 Jun;148(6):1763-70 [8669463.001]
  • [Cites] J Gastroenterol. 2005 Jul;40(7):744-51 [16082592.001]
  • [Cites] Gut. 2002 Jun;50(6):861-8 [12010891.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):34-43 [11781278.001]
  • [Cites] Development. 1993 Feb;117(2):461-70 [8101167.001]
  • [Cites] Oncogene. 1996 May 16;12(10):2137-46 [8668339.001]
  • (PMID = 20107842.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / MSX2 protein; 0 / RNA, Messenger
  •  go-up   go-down


24. Sedghizadeh PP, Wong D, Shuler CF, Linz V, Kalmar JR, Allen CM: Multifocal calcifying epithelial odontogenic tumor. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Aug;104(2):e30-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal calcifying epithelial odontogenic tumor.
  • The calcifying epithelial odontogenic tumor (CEOT), or Pindborg tumor, is a rare and benign odontogenic neoplasm that affects the jaw.
  • In this article, we present a unique case of CEOT affecting multiple sites in the maxilla and mandible of a 51-year-old white man.
  • [MeSH-major] Jaw Neoplasms / pathology. Odontogenic Tumors / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Rare Diseases

  • Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17630096.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Li H, Gu Y, Miki J, Hukku B, McLeod DG, Hei TK, Rhim JS: Malignant transformation of human benign prostate epithelial cells by high linear energy transfer alpha-particles. Int J Oncol; 2007 Sep;31(3):537-44
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of human benign prostate epithelial cells by high linear energy transfer alpha-particles.
  • In the present study, we examined the oncogenic transforming potency of alpha-particles using non-tumorigenic, telomerase-immortalized human benign prostate epithelial cells.
  • We report the malignant transformation of human benign prostate epithelial cells after a single exposure to 0.6 Gy dose of alpha-particles.
  • Transformed cells showed anchorage-independent growth in soft agar and induced progressively growing tumors when transplanted into SCID mice.
  • The tumors were characterized histologically as poorly differentiated adenocarcinomas.
  • The cell line derived from tumor (SCID 5015), like the unirradiated cells, expressed cytokeratin 5, 8 and 18, NKX3.1 and AMACR.
  • Prominent changes in chromosomes 6, 11 and 16, as well as mutations and deletions of the p53 gene were observed in the tumor outgrowth and tumor cells.
  • These findings provide the first evidence of malignant transformation of human benign prostate epithelial cells exposed to a single dose of alpha-particles.
  • [MeSH-minor] Animals. Cell Line, Transformed. Chromosome Aberrations. Humans. Male. Mice. Mice, SCID. Neoplasm Transplantation

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671680.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Greece
  •  go-up   go-down


26. Lombardi D, Piccioni M, Farina D, Morassi ML, Nicolai P: Oncocytic carcinoma of the maxillary sinus: a rare neoplasm. Eur Arch Otorhinolaryngol; 2006 Jun;263(6):528-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma of the maxillary sinus: a rare neoplasm.
  • Oncocytic neoplasms are tumors composed of oncocytes (i.e., epithelial cells with a large cytoplasm that is rich in mitochondria).
  • Most cases are benign and originate from the major salivary glands, while the minor salivary glands are rarely involved.
  • Biopsy was consistent with an unspecified salivary gland neoplasm.
  • A brief analysis of the literature was also accomplished in order to discuss treatment options and prognosis of this unusual neoplasm.
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Male. Middle Aged. Rare Diseases. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck Surg. 1988 Jul-Aug;10(6):427-31 [3220785.001]
  • [Cites] South Med J. 1980 Jun;73(6):803-6 [7394618.001]
  • [Cites] J Fr Ophtalmol. 1990;13(3):153-8 [2229900.001]
  • [Cites] Head Neck. 1996 Jul-Aug;18(4):374-80 [8780951.001]
  • [Cites] Otolaryngol Head Neck Surg. 1985 Apr;93(2):267-70 [3921922.001]
  • [Cites] Laryngoscope. 1979 Mar;89(3):372-6 [431244.001]
  • [Cites] Laryngoscope. 1973 Dec;83(12):1940-52 [4772101.001]
  • [Cites] Cancer. 1962 Sep-Oct;15:1019-27 [13904230.001]
  • [Cites] Z Krebsforsch. 1962;64:427-40 [13904235.001]
  • [Cites] J Laryngol Otol. 1979 Jul;93(7):729-34 [469401.001]
  • [Cites] Rev Laryngol Otol Rhinol (Bord). 1989;110(5):481-3 [2633254.001]
  • [Cites] Cancer. 1976 Sep;38(3):1306-17 [953970.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Jul;262(7):567-9 [15592856.001]
  • [Cites] Zentralbl Allg Pathol. 1990;136(7-8):703-6 [2089847.001]
  • [Cites] Arch Otolaryngol. 1968 Jul;88(1):71-3 [5660032.001]
  • (PMID = 16474973.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Mortuaire G, Pasquesoone X, Leroy X, Chevalier D: Respiratory epithelial adenomatoid hamartomas of the sinonasal tract. Eur Arch Otorhinolaryngol; 2007 Apr;264(4):451-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Respiratory epithelial adenomatoid hamartomas of the sinonasal tract.
  • We report the clinicopathologic features of two cases of respiratory epithelial adenomatoid harmartoma (REAH) of the sinonasal tract.
  • Histologically, these lesions were characterized by a glandular proliferation lined by ciliated respiratory epithelium originated from the surface epithelium.
  • Fine histopathological analysis is necessary to avoid aggressive surgery for this benign lesion.
  • [MeSH-major] Adenomatoid Tumor / pathology. Hamartoma / pathology. Paranasal Sinus Neoplasms / pathology. Respiratory Mucosa / pathology
  • [MeSH-minor] Adult. Endoscopy. Female. Humans. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 May;97(5):607-12 [15153874.001]
  • [Cites] Am J Otolaryngol. 2004 Jul-Aug;25(4):282-4 [15239039.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1995 Aug;104(8):639-45 [7639474.001]
  • [Cites] J Laryngol Otol. 2004 Jul;118(7):558-60 [15318966.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2003 Jun;67(6):669-72 [12745162.001]
  • [Cites] Acta Otolaryngol. 2002 Jun;122(4):398-400 [12125996.001]
  • [Cites] Rev Laryngol Otol Rhinol (Bord). 2004;125(1):45-8 [15244029.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2005 Jan;69(1):87-91 [15627453.001]
  • (PMID = 17089137.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Szporek BJ, Cieślik T, Jedrzejewski PW, Lipiarz LZ: [Calcifying epithelial odontogenic tumor (Pindborg tumor)]. Wiad Lek; 2005;58(7-8):458-61
Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Calcifying epithelial odontogenic tumor (Pindborg tumor)].
  • The calcifying epithelial odontogenic tumor (CEOT) is a rare benign odontogenic neoplasm which was first described by Pindborg in 1955 representing only 1% of all odontogenic tumors.
  • The tumor has an ectodermal odontogenic origin.
  • This tumor are considered benign but can be locally aggressive in nature with recurrence rates of 10-15% reported.
  • Since 1973 three cases only of the Pinborg tumor have been presented in the Polish literature.
  • We described the case of a 44-year-old man with Pindborg tumor in the right maxilla.
  • Standard x-ray examinations and CT scan were performed in order to obtain information about tumor's localization.
  • Autors discuss the radiologic features of calcifying epithelial odontogenic tumor and treatment method and the relevant literature.
  • [MeSH-major] Calcinosis / diagnosis. Maxillary Neoplasms / diagnosis. Odontogenic Tumors / diagnosis
  • [MeSH-minor] Adult. Humans. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425804.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


29. Shimanovich I, Krahl D, Rose C: Trichoadenoma of Nikolowski is a distinct neoplasm within the spectrum of follicular tumors. J Am Acad Dermatol; 2010 Feb;62(2):277-83
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trichoadenoma of Nikolowski is a distinct neoplasm within the spectrum of follicular tumors.
  • BACKGROUND: Trichoadenoma is a rare benign follicular tumor first described by Nikolowski 50 years ago.
  • Both trichoadenoma and desmoplastic trichoepithelioma are composed of cords of epithelial cells and cornifying cysts embedded in sclerotic stroma.
  • In trichoadenoma the cystic component predominates, while desmoplastic trichoepithelioma is a mostly solid neoplasm.
  • OBJECTIVE: The aim of this study was to investigate whether the morphologic overlap between trichoadenoma and desmoplastic trichoepithelioma translates into a similar immunohistochemical profile.
  • LIMITATIONS: This study is limited by the moderate number of these rare tumors available for immunohistochemical analysis.
  • Trichoadenoma is a distinct follicular tumor related but not identical to desmoplastic trichoepithelioma.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Head and Neck Neoplasms / pathology. Humans. Immunohistochemistry. Keratin-20 / metabolism. Male. Merkel Cells / pathology. Middle Aged. Neoplasms, Fibroepithelial / pathology. Receptors, Androgen / metabolism. Skin / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20115950.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Receptors, Androgen; 0 / human epithelial antigen-125
  •  go-up   go-down


30. Moreira PR, Guimarães MM, Gomes CC, Diniz MG, Brito JA, de Castro WH, Gomez RS: Methylation frequencies of cell-cycle associated genes in epithelial odontogenic tumours. Arch Oral Biol; 2009 Oct;54(10):893-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation frequencies of cell-cycle associated genes in epithelial odontogenic tumours.
  • OBJECTIVE: The benign epithelial odontogenic tumours constitute a group of lesions derived from epithelial elements of the tooth-forming apparatus.
  • This group includes lesions of different biological behaviour, such as ameloblastoma, calcifying cystic odontogenic tumour (CCOT) and adenomatoid odontogenic tumour (AOT).
  • The aim of this study was to investigate the methylation status of P16, P21, P27, P53 and RB1 genes in epithelial odontogenic tumours.
  • A high percentage of the odontogenic tumours analysed showed methylation of the P21 gene, in contrast to dental follicles.
  • CONCLUSIONS: Epithelial odontogenic tumours show a distinct methylation profile in cell-cycle associated genes.
  • In addition to this, the current findings show that epigenetic alterations are common events in epithelial odontogenic tumours.
  • [MeSH-major] Cell Cycle Proteins / genetics. DNA Methylation / genetics. DNA, Neoplasm / metabolism. Neoplasm Proteins / genetics. Odontogenic Tumors / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Ameloblastoma / genetics. Ameloblastoma / metabolism. Dental Sac / metabolism. Epithelial Cells / metabolism. Humans. Odontogenic Cyst, Calcifying / genetics. Odontogenic Cyst, Calcifying / metabolism. Polymerase Chain Reaction / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19679296.001).
  • [ISSN] 1879-1506
  • [Journal-full-title] Archives of oral biology
  • [ISO-abbreviation] Arch. Oral Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins
  •  go-up   go-down


31. Xie D, Yang GF, Chen YQ, Jiang LF, Xiao LZ: [Significance and mechanisms of overexpression of PAK1 gene in epithelial ovarian neoplasms]. Zhonghua Zhong Liu Za Zhi; 2006 Dec;28(12):911-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance and mechanisms of overexpression of PAK1 gene in epithelial ovarian neoplasms].
  • OBJECTIVE: To investigate the significance and mechanisms of overexpression of p21-activated kinase 1 gene (PAK1) in epithelial ovarian neoplasms.
  • METHODS: Immunohistochemistry, fluorescence in situ hybridization and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling methods were used to examine the protein expression and amplification of PAK1 and cell apoptosis in 30 benign ovarian adenomas, 20 borderline tumors and 80 ovarian carcinomas by tissue microarray.
  • RESULTS: In immunohistochemistry study, overexpression of PAK1 protein was observed in 7 (25.9%) informative benign ovarian adenomas, 7 (36.8%) borderline tumors and 53 (68.8%) ovarian carcinomas.
  • A significant inverse correlation of PAK1 overexpression and cell apoptosis was observed in these epithelial ovarian neoplasm cohorts (P = 0.002).
  • In addition, 27/31 (87.1%) poorly differentiated (G3) carcinomas showed overexpression of PAK1, the frequency was significantly higher than that in tumors of G1 - G2 (26/46, 56.5% , P =0.01).
  • None of the borderline and benign ovarian tumors showed PAK1 amplification.
  • CONCLUSION: Overexpression of PAK1 protein may be involved in the tumorigenesis of epithelial ovarian neoplasms and it is associated closely with the malignant histological phenotype of ovarian carcinomas.
  • Mechanism other than gene amplification of PAK1 may play a more important role in the regulation of protein expression of PAK1 in ovarian tumors.
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Cystadenocarcinoma, Mucinous / genetics. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Female. Gene Amplification. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. In Situ Nick-End Labeling. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17533742.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.11.1 / PAK1 protein, human; EC 2.7.11.1 / p21-Activated Kinases
  •  go-up   go-down


32. Hagemann T, Binder C, Binder L, Pukrop T, Trümper L, Grimshaw MJ: Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol; 2005 Nov;24(11):766-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells.
  • There is increased staining of endothelins (ET-1, -2, and -3) and receptors (ET-RA and -RB) in invasive breast tumors compared to nonneoplastic tissue, and ETs stimulate MCF-7 cell invasion in vitro.
  • We analyzed ETstimulation of benign and transformed mammary epithelial cells, and whether expression of ETs is sufficient to induce invasiveness.
  • In breast cancer patient serum, ET-1 was increased in those patients with lymph node metastases compared to those with no lymph node involvement; ETs, however, had no mitogenic effect on breast tumor cell lines in vitro.
  • The benign mammary epithelial cell line, hTERT-HME1, and the poorly invasive breast tumor cell line MCF-7 secreted low levels of ET-1, while the invasive cell lines SKBR3 and MDAMB231 secreted high levels.
  • In contrast to transformed cells, ET stimulation or overexpression did not induce an invasive phenotype in benign cells.
  • Benign cells do not respond to ETs, and ET expression is not sufficient to induce invasion; however, the level of ET production by tumor cells correlates with their invasiveness, and increasing expression of the ET axis promotes breast tumor cell invasion via both receptors, while MMP-14 is induced via ET-RA.
  • [MeSH-major] Breast Neoplasms / metabolism. Endothelins / biosynthesis. Epithelial Cells / metabolism. Receptor, Endothelin A / biosynthesis. Receptor, Endothelin B / biosynthesis
  • [MeSH-minor] Calcium / metabolism. Cell Line. Cell Line, Tumor. Endothelin-1 / blood. Endothelin-1 / metabolism. Enzyme Induction. Female. Humans. Lymphatic Metastasis. Mammary Glands, Human / metabolism. Mammary Glands, Human / pathology. Matrix Metalloproteinases / biosynthesis. Neoplasm Invasiveness. Phenotype. Signal Transduction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274297.001).
  • [ISSN] 1044-5498
  • [Journal-full-title] DNA and cell biology
  • [ISO-abbreviation] DNA Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endothelin-1; 0 / Endothelins; 0 / Receptor, Endothelin A; 0 / Receptor, Endothelin B; EC 3.4.24.- / Matrix Metalloproteinases; SY7Q814VUP / Calcium
  •  go-up   go-down


33. Poomsawat S, Punyasingh J: Calcifying epithelial odontogenic tumor: an immunohistochemical case study. J Mol Histol; 2007 Mar;38(1):103-9
Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcifying epithelial odontogenic tumor: an immunohistochemical case study.
  • Calcifying epithelial odontogenic tumor (CEOT) is a rare benign odontogenic tumor.
  • Histologically, the case showed sheets of polyhedral epithelial cells with deep eosinophilic cytoplasm and prominent nuclei.
  • Globules of amyloid-like material among the tumor cells were prominent.
  • Tumor cells expressed laminins 1 and 5, fibronectin, cytokeratins and vimentin.
  • A number of dendritic cells among sheets of tumor cells were revealed with strong staining for S-100 protein and CD 1a.
  • [MeSH-major] Mandibular Neoplasms / metabolism. Mandibular Neoplasms / pathology. Neoplasm Proteins / metabolism. Odontogenic Cyst, Calcifying / metabolism. Odontogenic Cyst, Calcifying / pathology
  • [MeSH-minor] Adult. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cytoplasm / metabolism. Cytoplasm / pathology. Dendritic Cells / metabolism. Dendritic Cells / pathology. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Pathol Med. 1993 Sep;22(8):378-83 [8283404.001]
  • [Cites] J Oral Pathol. 1985 Feb;14(2):133-40 [2580070.001]
  • [Cites] Oral Dis. 2001 May;7(3):171-6 [11495193.001]
  • [Cites] Biotech Histochem. 1995 May;70(3):114-8 [7548432.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Nov;104(5):666-75 [17150384.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Sep;63(9):1377-82 [16122606.001]
  • [Cites] J Lab Clin Med. 2003 Nov;142(5):348-55 [14647039.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Mar;95(3):332-9 [12627106.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Oct;102(4):e12-5 [16997086.001]
  • [Cites] Hum Pathol. 1983 Feb;14(2):108-26 [6339357.001]
  • [Cites] J Oral Pathol Med. 1990 Oct;19(9):430-4 [2269939.001]
  • [Cites] J Oral Pathol Med. 1992 Mar;21(3):113-9 [1374797.001]
  • [Cites] Oral Oncol. 2000 Jan;36(1):17-26 [10889914.001]
  • [Cites] J Oral Pathol. 1981 Dec;10(6):417-29 [6174718.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):501-5 [3539313.001]
  • [Cites] J Oral Pathol Med. 1991 Feb;20(2):93-5 [2016701.001]
  • [Cites] J Oral Pathol. 1982;11(5):399-406 [6815318.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Mar;93(3):287-95 [11925538.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Jun;63(6):852-5 [15944987.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Sep;63(9):1361-8 [16122602.001]
  • [Cites] J Oral Pathol Med. 1999 Apr;28(4):187-91 [10235374.001]
  • [Cites] Int Dent J. 2004 Dec;54(6):457-60 [15633503.001]
  • [Cites] J Oral Pathol. 1988 May;17(5):236-40 [2462621.001]
  • [Cites] J Oral Pathol. 1983 Oct;12(5):366-74 [6415257.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):872-6 [10835524.001]
  • [Cites] Connect Tissue Res. 1995;32(1-4):9-15 [7554939.001]
  • [Cites] Oral Dis. 2003 Jan;9(1):1-6 [12617250.001]
  • (PMID = 17318341.001).
  • [ISSN] 1567-2379
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


34. Sui L, Dong Y, Watanabe Y, Yamaguchi F, Sugimoto K, Tokuda M: Alteration and clinical relevance of PTEN expression and its correlation with survivin expression in epithelial ovarian tumors. Oncol Rep; 2006 Apr;15(4):773-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration and clinical relevance of PTEN expression and its correlation with survivin expression in epithelial ovarian tumors.
  • The tumor suppressor PTEN, phosphatase and tensin homolog on chromosome 10, plays an essential role in regulating signaling pathways involved in cell growth and apoptosis and is inactivated in a wide variety of tumors.
  • Survivin, a member of the inhibitor of apoptosis protein family (IAP), is associated with cell proliferation, and overexpressed in common human tumors.
  • We have previously investigated the role of survivin expression in epithelial ovarian tumors.
  • In this study, we evaluated the alteration and clinical relevance of PTEN expression and further assessed its correlation with survivin expression in epithelial ovarian tumors.
  • Immunohistochemical analysis was performed in 103 cases of ovarian tumors, and 26 of the 103 cases were evaluated by Western blot analysis.
  • PTEN expression was reduced from benign to malignant ovarian tumors (p=0.0003), and an inverse correlation between PTEN and survivin was found in benign, borderline, and malignant tumors (p=0.004, p=0.015 and p=0.0005, respectively).
  • PTEN expression was significantly associated with tumor grade (p=0.001), histological subtype (p=0.037), ascites (p=0.038), and residual disease (p=0.0006).
  • Our results suggest that the altered PTEN expression and its inverse correlation with survivin may be involved in the development and progression of ovarian tumors, and the combined detection of PTEN and survivin proteins might be more valuable in the evaluation of malignancy and prognosis in epithelial ovarian tumors.
  • [MeSH-major] Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / pathology. PTEN Phosphohydrolase / biosynthesis
  • [MeSH-minor] Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Middle Aged. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525657.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


35. Ruhin-Poncet B, Ghoul-Mazgar S, Hotton D, Capron F, Jaafoura MH, Goubin G, Berdal A: Msx and dlx homeogene expression in epithelial odontogenic tumors. J Histochem Cytochem; 2009 Jan;57(1):69-78

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Msx and dlx homeogene expression in epithelial odontogenic tumors.
  • Epithelial odontogenic tumors are rare jaw pathologies that raise clinical diagnosis and prognosis dilemmas notably between ameloblastomas and clear cell odontogenic carcinomas (CCOCs).
  • Although Msx1 expression imitates normal cell differentiation in these tumors, other genes showed a distinct pattern depending on the type of tumor and the tissue involved.
  • In benign ameloblastomas, ISH localized Dlx3 transcripts and inconstantly detected Msx2 transcripts in epithelial cells.
  • In the CCOC, ISH established a lack of both Dlx3 and Msx2 transcripts but allowed identification of the antisense transcript of Msx1, which imitates the same scheme of distribution between mesenchyme and epithelium as in the cup stage of tooth development.
  • Bmp4 was always expressed in all the tumors.
  • Based on the established roles of Msx and Dlx transcription factors in dental cell fates, these data suggest that their altered expression is a proposed trail to explain the genesis and/or the progression of odontogenic tumors.
  • [MeSH-major] Homeodomain Proteins / biosynthesis. Jaw Neoplasms / metabolism. MSX1 Transcription Factor / biosynthesis. Odontogenic Tumors / metabolism. Transcription Factors / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Ameloblastoma / metabolism. Bone Morphogenetic Protein 2 / biosynthesis. Bone Morphogenetic Protein 4 / biosynthesis. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Neoplasm Recurrence, Local. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1996 Aug;13(4):417-21 [8696335.001]
  • [Cites] Stem Cells. 1996 May;14(3):281-91 [8724694.001]
  • [Cites] Development. 1996 Oct;122(10):3035-44 [8898217.001]
  • [Cites] J Cell Biol. 1996 Dec;135(6 Pt 2):1879-87 [8991098.001]
  • [Cites] Hum Mol Genet. 1998 Mar;7(3):563-9 [9467018.001]
  • [Cites] Development. 1998 Jan;125(2):161-9 [9486790.001]
  • [Cites] Development. 1998 May;125(9):1627-35 [9521901.001]
  • [Cites] Pathol Int. 1998 Aug;48(8):618-22 [9736409.001]
  • [Cites] Development. 1998 Nov;125(21):4325-33 [9753686.001]
  • [Cites] J Dent Res. 1999 Jan;78(1):20-30 [10065942.001]
  • [Cites] Development. 1999 Sep;126(17):3831-46 [10433912.001]
  • [Cites] J Oral Pathol Med. 1999 Sep;28(8):343-9 [10478958.001]
  • [Cites] J Cell Biol. 2004 Dec 6;167(5):973-83 [15583034.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):749-57 [15705871.001]
  • [Cites] Am J Med Genet A. 2005 Mar 1;133A(2):138-41 [15666299.001]
  • [Cites] Cancer Invest. 2005;23(3):222-8 [15945508.001]
  • [Cites] J Dent Res. 2005 Dec;84(12):1117-26 [16304440.001]
  • [Cites] Bone. 2005 Dec;37(6):799-809 [16172034.001]
  • [Cites] Orthod Craniofac Res. 2006 Feb;9(1):52-6 [16420275.001]
  • [Cites] World J Gastroenterol. 2005 Nov 21;11(43):6867-70 [16425399.001]
  • [Cites] Oral Dis. 2006 Mar;12(2):163-70 [16476038.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Mar;64(3):484-94 [16487813.001]
  • [Cites] J Oral Pathol Med. 2006 May;35(5):278-85 [16630291.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Sep;45(9):846-55 [16804919.001]
  • [Cites] Pathol Int. 2006 Dec;56(12):732-7 [17096730.001]
  • [Cites] Minerva Stomatol. 2006 Sep;55(9):503-13 [17146429.001]
  • [Cites] J Biol Chem. 2006 Dec 29;281(52):40515-26 [17060321.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e486 [17194187.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Mar;22(3):389-94 [17295772.001]
  • [Cites] Oncol Rep. 2007 Apr;17(4):753-60 [17342311.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Apr;65(4):777-83 [17368379.001]
  • [Cites] Pediatr Res. 1999 Dec;46(6):650-6 [10590019.001]
  • [Cites] J Histochem Cytochem. 2000 Feb;48(2):277-84 [10639494.001]
  • [Cites] Nat Genet. 2000 Apr;24(4):342-3 [10742093.001]
  • [Cites] Nat Genet. 2000 Apr;24(4):391-5 [10742104.001]
  • [Cites] Gene. 2000 Oct 3;256(1-2):1-11 [11054529.001]
  • [Cites] J Dent Res. 2007 Apr;86(4):331-5 [17384027.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jun;103(6):799-807 [17448710.001]
  • [Cites] Bone. 2007 Nov;41(5):851-9 [17878071.001]
  • [Cites] Hum Pathol. 2008 Mar;39(3):350-8 [18187185.001]
  • [Cites] Cell. 2000 Dec 22;103(7):1099-109 [11163185.001]
  • [Cites] Dev Genes Evol. 2000 May;210(5):270-5 [11180832.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar16;281(5):1234-40 [11243867.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):10016-24 [11113121.001]
  • [Cites] Bioessays. 2001 Jun;23(6):481-93 [11385628.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7336-41 [11390985.001]
  • [Cites] DNA Cell Biol. 2001 Jun;20(6):359-65 [11445007.001]
  • [Cites] Int J Dev Biol. 2001 Jun;45(4):681-4 [11461005.001]
  • [Cites] Oral Dis. 2001 May;7(3):171-6 [11495193.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 15;30(2):515-22 [11788714.001]
  • [Cites] J Dent Res. 2002 Aug;81(8):525-30 [12147741.001]
  • [Cites] J Neurosci Res. 2002 Sep 15;69(6):803-9 [12205674.001]
  • [Cites] Stem Cells. 2002;20(5):364-79 [12351808.001]
  • [Cites] Oncol Rep. 2003 Jul-Aug;10(4):973-7 [12792755.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2B):1479-88 [12820413.001]
  • [Cites] J Dent Res. 2003 Jul;82(7):551-7 [12821718.001]
  • [Cites] J Craniofac Surg. 2003 May;14(3):356-62 [12826807.001]
  • [Cites] J Leukoc Biol. 2003 Aug;74(2):302-5 [12885948.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1707-12 [14578169.001]
  • [Cites] J Oral Pathol Med. 2004 May;33(5):292-9 [15078490.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2B):955-62 [15161049.001]
  • [Cites] J Oral Pathol Med. 2004 Jul;33(6):360-7 [15200485.001]
  • [Cites] Oral Oncol. 2004 Sep;40(8):841-6 [15288841.001]
  • [Cites] J Oral Pathol. 1985 Sep;14(8):603-14 [3930670.001]
  • [Cites] J Electron Microsc (Tokyo). 1990;39(5):404-7 [2084197.001]
  • [Cites] Cell. 1993 Oct 8;75(1):45-58 [8104708.001]
  • [Cites] Nat Genet. 1994 Apr;6(4):348-56 [7914451.001]
  • [Cites] J Exp Zool. 1994 Nov 1;270(3):273-84 [7964557.001]
  • [Cites] Nature. 1994 Dec 15;372(6507):684-6 [7990961.001]
  • [Cites] Connect Tissue Res. 1995;32(1-4):137-43 [7554910.001]
  • [Cites] Development. 1996 Jan;122(1):121-9 [8565823.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):149-53 [8563752.001]
  • [Cites] Oncogene. 1996 May 16;12(10):2137-46 [8668339.001]
  • (PMID = 18854600.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BMP2 protein, human; 0 / BMP4 protein, human; 0 / Bone Morphogenetic Protein 2; 0 / Bone Morphogenetic Protein 4; 0 / Distal-less homeobox proteins; 0 / Homeodomain Proteins; 0 / MSX1 Transcription Factor; 0 / MSX2 protein; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2605714
  •  go-up   go-down


36. Jaffar R, Mohanty SK, Khan A, Fischer AH: Hemosiderin laden macrophages and hemosiderin within follicular cells distinguish benign follicular lesions from follicular neoplasms. Cytojournal; 2009;6:3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemosiderin laden macrophages and hemosiderin within follicular cells distinguish benign follicular lesions from follicular neoplasms.
  • BACKGROUND: Published criteria to distinguish benign colloid nodules from follicular neoplasms emphasize only three interdependent features: size of follicles, amount of colloid, and cellularity.
  • Three of these four had equivocal features of a benign colloid nodule histologically.
  • Hemosiderin within follicular epithelial cells was present in 18% (18 of 101) of goiters, whereas none of the 64 follicular neoplasms had intraepithelial hemosiderin (P<.0003).
  • CONCLUSIONS: If papillary thyroid carcinoma and Hürthle cell neoplasm are ruled out, our findings indicate that the presence of hemosiderin virtually excludes a clinically significant follicular neoplasm.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytojournal. 2008;5:6 [18394201.001]
  • [Cites] Diagn Cytopathol. 2007 Aug;35(8):525-8 [17636488.001]
  • [Cites] Cytopathology. 2007 Apr;18(2):105-11 [17397495.001]
  • [Cites] Cytopathology. 1999 Jun;10(3):171-9 [10390065.001]
  • [Cites] J Ultrasound Med. 2003 Oct;22(10):1083-90 [14606565.001]
  • [Cites] Acta Cytol. 1992 Mar-Apr;36(2):142-6 [1542996.001]
  • [Cites] Acta Cytol. 1989 Jan-Feb;33(1):53-60 [2916371.001]
  • [Cites] Cancer. 1986 Mar 15;57(6):1164-70 [3943039.001]
  • [Cites] Acta Cytol. 1990 May-Jun;34(3):345-51 [2343690.001]
  • [Cites] Mayo Clin Proc. 1994 Jan;69(1):44-9 [8271850.001]
  • (PMID = 19495407.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2678825
  • [Keywords] NOTNLM ; Benign colloid nodule / follicular cells / hemosiderin laden macrophages / hemosiderin within follicular neoplasms / macrophages
  •  go-up   go-down


37. Zachariah RR, Schmid S, Buerki N, Radpour R, Holzgreve W, Zhong X: Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors. Obstet Gynecol; 2008 Oct;112(4):843-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors.
  • OBJECTIVE: To analyze the levels of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in patients with benign and malignant ovarian tumors using a gold-standard assay and to investigate whether quantitative alterations of the circulating cell-free species have values in the management of the patients.
  • We developed a quantitative, multiplex polymerase chain reaction to measure the levels of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in serum and plasma of patients with epithelial ovarian cancer, benign epithelial ovarian tumors, or endometriosis.
  • The levels of the circulating cell-free DNA were compared with those of a healthy, age-matched control group.
  • RESULTS: The patients with epithelial ovarian cancer had significantly higher amounts of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in plasma compared with the healthy control group (mean of nuclear DNA 10,723/2,591 and mean of mitochondrial DNA 4,918,978/2,294,264, P=.009 and 0.022, respectively) and with the other group with benign ovarian diseases (mean of nuclear DNA 10,723/2,965 and mean of mitochondrial DNA 4,918,978/1,597,551, P=.027 and 0.002, respectively).
  • However, no relationship between levels of the circulating cell-free DNA and the pathological parameters as well as CA 125 measurement in patients with epithelial ovarian cancer was found.
  • A significant difference between the epithelial ovarian cancer and endometriosis group was found in circulating cell-free mitochondrial DNA but not in circulating cell-free nuclear DNA (mean of mitochondrial DNA 4,918,978/2,273,988 and mean of nuclear DNA 10,723/3,291, P=.013 and 0.105, respectively).
  • CONCLUSION: Elevated levels of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in epithelial ovarian cancer may have diagnostic value.
  • [MeSH-major] DNA, Mitochondrial / blood. DNA, Neoplasm / blood. Ovarian Neoplasms / blood. Polymerase Chain Reaction / methods
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Cell-Free System / chemistry. Endometriosis / blood. Female. Humans. ROC Curve

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827127.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Mitochondrial; 0 / DNA, Neoplasm
  •  go-up   go-down


38. Chetty R, Serra S: Intraductal tubular adenoma (pyloric gland-type) of the pancreas: a reappraisal and possible relationship with gastric-type intraductal papillary mucinous neoplasm. Histopathology; 2009 Sep;55(3):270-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal tubular adenoma (pyloric gland-type) of the pancreas: a reappraisal and possible relationship with gastric-type intraductal papillary mucinous neoplasm.
  • Three cases of ITA are presented, the literature reviewed and their association with intraductal papillary mucinous neoplasm (IPMN) is postulated.
  • METHODS AND RESULTS: ITA is composed of tightly packed tubular structures with focal cystic dilation and papillary areas lined by gastric/pyloric epithelium showing minimal to mild cytological atypia.
  • The coexistence of ITA and IPMN and the similarities of their epithelial lining (gastric/pyloric mucosa) suggest a possible pathogenic link.
  • ITA could represent a localized, polypoid form of gastric-type IPMN.It is a benign lesion with no evidence of invasion and no direct tumour-related deaths.
  • [MeSH-minor] Aged. Epithelial Cells / pathology. Female. Humans. Male. Middle Aged. Neoplasms, Multiple Primary. Pancreatectomy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2010 Jun;56(7):968-9; author reply 969 [20636797.001]
  • (PMID = 19723141.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Serin IS, Tanriverdi F, Yilmaz MO, Ozcelik B, Unluhizarci K: Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women. Gynecol Endocrinol; 2008 Mar;24(3):117-21
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
  • AIMS: The aims of the present study were to determine the serum concentrations of insulin-like growth factor-I (IGF-I), insulin-like growth factor binding protein-3 (IGFBP-3) and leptin and insulin resistance in benign and malignant epithelial ovarian tumors, and to discuss the use of these markers in benign-malignant tumor differentiation.
  • METHODS: Forty-seven postmenopausal women with ovarian tumor and 31 age-matched, postmenopausal, healthy controls were included in this study.
  • RESULTS: According to postoperative histopathology results, the patients were divided into malignant (n = 23), benign (n = 24) and control (n = 31) groups.
  • Serum concentrations of CA-125 were elevated in the malignant group compared with the benign ovarian tumor and control groups (p < 0.05).
  • In contrast, serum IGF-I concentrations were significantly decreased in patients with malignant and benign ovarian tumors compared with controls (p < 0.05).
  • Serum IGFBP-3 concentrations were also found to be lower in women with malignant ovarian tumors than in women with benign tumors (p < 0.05).
  • Serum leptin did not differ among patients with malignant-benign tumors and controls (p > 0.05).
  • CONCLUSION: Serum leptin and HOMA score have not been found to be valid indicators in ovarian tumors.
  • However, the present data suggest that low concentrations of IGF-I and IGFBP-3 could be a reliable marker to differentiate benign from malignant ovarian tumors.
  • [MeSH-major] Insulin-Like Growth Factor Binding Protein 3 / blood. Insulin-Like Growth Factor I / analysis. Leptin / blood. Neoplasms, Glandular and Epithelial / blood. Ovarian Neoplasms / blood. Postmenopause / blood
  • [MeSH-minor] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Female. Homeostasis. Humans. Insulin Resistance. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18335323.001).
  • [ISSN] 0951-3590
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Leptin; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


40. Badiglian Filho L, Oshima CT, De Oliveira Lima F, De Oliveira Costa H, De Sousa Damião R, Gomes TS, Gonçalves WJ: Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Oncol Rep; 2009 Feb;21(2):313-20
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer.
  • In order to analyze the canonical and noncanonical Wnt pathway in normal ovary, benign ovarian tumor and ovarian cancer, we evaluated the immunohistochemical expression of Wnt1, Frizzled-1 (FZD1), Wnt5a, Frizzled-5 (FZD5) and beta-catenin.
  • The patients were divided in three groups: group A, epithelial ovarian cancer (n=38); group B, benign epithelial neoplasia (n=28); and group C, normal ovaries (n=26).
  • [MeSH-major] Biomarkers, Tumor / analysis. Frizzled Receptors / biosynthesis. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Wnt Proteins / biosynthesis. beta Catenin / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Neoplasm Staging. Ovary. Prognosis. Signal Transduction / physiology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148501.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Frizzled Receptors; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


41. Coronado Martín PJ, Fasero Laiz M, García Santos J, Ramírez Mena M, Vidart Aragón JA: [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer]. Med Clin (Barc); 2007 Jan 13;128(1):1-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
  • [Transliterated title] Grado de expresión y valor pronóstico de las proteínas p53 y HER2/neu en el tejido ovárico benigno y en el cáncer de ovario.
  • BACKGROUND AND OBJECTIVE: To investigate the prognostic value of p53 and HER2/neu overexpression in epithelial ovarian cancer (EOC).
  • PATIENTS AND METHOD: p53 and HER2/neu immunostaining were performed in 198 tissue samples, 124 EOC, 44 benign ovarian tumors and 30 normal ovaries.
  • RESULTS: Neither p53 nor HER2/neu overexpression was seen in the benign ovarian tumors.
  • [MeSH-major] Cystadenoma, Mucinous / genetics. Cystadenoma, Serous / genetics. Ovarian Neoplasms / genetics. Receptor, ErbB-2 / genetics. Teratoma / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Aged. Biomarkers, Tumor. Confidence Intervals. Endometriosis / genetics. Endometriosis / pathology. Endometriosis / surgery. Female. Follow-Up Studies. Genes, p53. Humans. Immunohistochemistry. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Ovarian Diseases / genetics. Ovarian Diseases / pathology. Ovarian Diseases / surgery. Prognosis. Proportional Hazards Models. Risk. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17266884.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


42. Zhen B, Shen Y, Zhang YM, Zhu CH, Liu ZL: [Analysis of the differences in the expression of HSP27 and c-kit between benign prostatic hyperplasia and prostatic cancer tissues]. Zhonghua Nan Ke Xue; 2006 May;12(5):416-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the differences in the expression of HSP27 and c-kit between benign prostatic hyperplasia and prostatic cancer tissues].
  • OBJECTIVE: To examine the differences in the expression of HSP27 and c-kit between benign prostatic hyperplasia (BPH) and prostatic cancer (PCa) tissues and to analyse the relationship between their expression and BPH and PCa, especially the relationship with the occurrence, development, prognosis and treatment of PCa.
  • The glandular epithelium stained very strongly positively and the stroma stained positively.
  • The staining for c-kit in BPH tissues was located in the cytoplasm of smooth muscle cells, and in PCa tissues was located in epithelial cells.
  • CONCLUSION: The expression level of HSP27 and c-kit was highly correlated with the process of the development from BPH to PCa, and also correlated with tumor grades and stages.
  • [MeSH-major] Heat-Shock Proteins / biosynthesis. Neoplasm Proteins / biosynthesis. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / biosynthesis

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755871.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HSP27 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Heat-Shock Proteins; 0 / Neoplasm Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


43. Yang Y, Nie X, Lu J, Lu XY, Wei YY, Wang H, Han ZH, Chen ZH, Zheng J: [Mixed epithelial and stromal tumor of kidney]. Zhonghua Bing Li Xue Za Zhi; 2006 Jan;35(1):29-31
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mixed epithelial and stromal tumor of kidney].
  • OBJECTIVE: To study the clinicopathological features and differential diagnoses of mixed epithelial and stromal tumor of the kidney.
  • METHODS: Clinical and pathological characteristics of 4 cases of mixed epithelial and stromal tumor of the kidney were studied.
  • Grossly the tumors had a solid and cyst appearance.
  • Microscopically, the tumors were composed of a mixture of stromal and epithelial elements.
  • The epithelial elements were variable in cell types including cuboidal, hobnail and columnar cells.
  • One case showed Müllerian and intestinal epithelial differentiations.
  • Stromal elements essentially consisted of spindle cells, with thick-walled blood vessels and bands of smooth muscle cells as distinctive features of the tumor.
  • Immunohistochemical staining revealed that the epithelial components were positive for AE1/AE3, whereas the stromal components were positive for ER, PR, and SMA.
  • CONCLUSIONS: Mixed epithelial and stromal tumor of the kidney is a benign neoplasm with distinct histopathological features.
  • [MeSH-major] Kidney Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Neoplasms, Glandular and Epithelial / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608646.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


44. Shariat SF, Ashfaq R, Roehrborn CG, Slawin KM, Lotan Y: Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol; 2005 Nov;174(5):2046-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
  • PURPOSE: We assessed the differential expression of survivin and other apoptotic markers in stromal and epithelial compartments of benign prostatic hyperplasia (BPH) and normal prostate tissue.
  • RESULTS: Survivin and Bcl-2 expression increased incrementally from normal prostate to epithelial BPH to stromal BPH.
  • Caspase-3 expression was higher in BPH epithelium than in BPH stroma, which in turn was higher than that in normal prostate.
  • Ki-67 was significantly over expressed in BPH stroma and epithelium.
  • Survivin expression in BPH tissue correlated with International Prostate Symptom Score, quality of life, post-void residual urine volume, maximum urine flow rate and transforming growth factor-beta1 expression.
  • [MeSH-major] Caspases / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Prostatic Hyperplasia / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217391.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


45. Faquin WC, Cibas ES, Renshaw AA: "Atypical" cells in fine-needle aspiration biopsy specimens of benign thyroid cysts. Cancer; 2005 Apr 25;105(2):71-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Atypical" cells in fine-needle aspiration biopsy specimens of benign thyroid cysts.
  • Most are benign nodules with degenerative changes in a multinodular goiter.
  • Fine-needle aspiration biopsy (FNAB) specimens from these cystic nodules usually are easily interpreted as benign.
  • However, occasionally, cells with atypical features are encountered, increasing the possibility of a cystic malignant neoplasm.
  • To the authors' knowledge, the microscopic features of these benign cells, presumed to be of cyst-lining origin, have not been well described to date.
  • To refine the description of their morphologic features, with the belief that better recognition will avoid unnecessary surgery, the authors examined the cytologic and corresponding histologic features of thyroid cysts with "atypical" cells.
  • Seventy-five specimens with subsequent histologic correlation showing a benign cystic thyroid nodule were selected for study.
  • However, in 29% of these specimens, a papillary or Hurthle cell neoplasm could not be excluded.
  • The cytologic features of the atypical cells most often resembled classic reparative epithelial cells consistent with a cyst-lining origin.
  • In contrast to the atypical cells from benign cysts, cystic papillary carcinomas lacked the repair-like spindled cytomorphology, and showed nuclear crowding (100%), as well as papillary microarchitecture (50%), and rare intranuclear pseudoinclusions (42%).
  • Immunohistochemical staining of a subset of the resected thyroid cysts showed that the cyst-lining cells were positive for keratin and thyroglobulin, consistent with thyroid follicular cells.
  • CONCLUSIONS: Atypical cyst-lining cells were found to have characteristic features (e.g., distinct cell borders, elongated shape, eosinophilic cytoplasm, and distinct nucleoli) and lacked nuclear crowding, intranuclear pseudoinclusions, and papillary architecture that, in many specimens, allowed them to be recognized as benign.
  • The authors recommended that the subset of cells with the characteristic features described in the current study be reported as "consistent with benign cyst lining cells".
  • [MeSH-major] Biopsy, Fine-Needle. Cysts / pathology. Thyroid Diseases / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 American Cancer Society.
  • [CommentIn] Cancer. 2006 Feb 25;108(1):72; author reply 73 [16400633.001]
  • (PMID = 15662703.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Plaza JA, Wakely PE Jr, Suster S: Lipoblastic nerve sheath tumors: report of a distinctive variant of neural soft tissue neoplasm with adipocytic differentiation. Am J Surg Pathol; 2006 Mar;30(3):337-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipoblastic nerve sheath tumors: report of a distinctive variant of neural soft tissue neoplasm with adipocytic differentiation.
  • Benign nerve sheath tumors of soft tissue can occasionally adopt unusual or unfamiliar morphologic appearances that may introduce difficulties for diagnosis, such as multinucleation, bizarre nuclei, intranuclear vacuoles, and other degenerative changes.
  • Tumor cells adopting a signet-ring or lipoblast-like configuration, however, are mostly associated with epithelial malignancies, liposarcoma and melanoma, and have been only rarely observed in spindle cell tumors of soft tissue.
  • We report 5 cases of benign nerve sheath neoplasms that displayed prominent signet-ring cells with lipoblast-like features.
  • Four tumors predominantly showed features of schwannoma and one of neurofibroma; however, intimately admixed with the spindle cell population, there were also numerous scattered mature adipocytes as well as lipoblast-like cells displaying a signet-ring cell appearance.
  • The presence of mature fat and signet-ring lipoblast-like cells within a nerve sheath neoplasm is quite rare and may signify a process of aberrant differentiation.
  • Neurogenic tumors should be added in the differential diagnosis of spindle cell tumors capable of displaying prominent signet-ring cell features.

  • Genetic Alliance. consumer health - Nerve sheath neoplasm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538053.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Păun I, Mogoş D, Păun M, Teodorescu M, Florescu M, Tenovici M, Mogoş G: [Diseases mimicking advanced-stage epithelial ovarian cancer]. Chirurgia (Bucur); 2010 Jul-Aug;105(4):541-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diseases mimicking advanced-stage epithelial ovarian cancer].
  • [Transliterated title] Afecţiuni mimând cancerul ovarian epitelial în stadiu avansat.
  • This paper draws attention towards 3 cases with different pathologies all of which suggesting however both clinically and by imaging means as the most likely diagnosis advanced-stage epithelial ovarian cancer since all these three postmenopausal women had been admitted to the hospital with ascites, pelvic masses and deterioration of the physical wellbeing (fatigue, decreased appetite, weight loss, pallor).
  • Findings during exploratory laparotomy on all these three pacients included ascites (hemorragic in one case) diffuse tumorous implants throughout the abdominal and pelvic peritoneal surfaces (in two cases) and the ovarian tumour.
  • Postoperatively, the final histopathologic diagnoses consisted of primary peritoneal carcinoma (one pacient), peritoneal tuberculosis (TB, one pacient) and hepatic cirrosis with an incidental benign adnexial mass (one pacient).
  • Moreover, nonmalignant ovarian tumours were certified in all three cases under current presentation.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Antitubercular Agents / therapeutic use. Ascites / diagnosis. Diagnosis, Differential. Diagnostic Errors. Drug Therapy, Combination. Female. Humans. Middle Aged. Neoplasm Staging. Ovariectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20941979.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antitubercular Agents
  •  go-up   go-down


48. Cai Z, Zhou Y, Lei T, Chiu JF, He QY: Mammary serine protease inhibitor inhibits epithelial growth factor-induced epithelial-mesenchymal transition of esophageal carcinoma cells. Cancer; 2009 Jan 1;115(1):36-48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammary serine protease inhibitor inhibits epithelial growth factor-induced epithelial-mesenchymal transition of esophageal carcinoma cells.
  • An epithelial growth factor (EGF)-induced epithelial-mesenchymal transition (EMT) model was used to mimic some aspects of the metastatic process in vitro.
  • RESULTS: The introduction of maspin into EC109 cells was able to inhibit EGF-induced EMT and altered cell growth characteristics, including the serum dependence, proliferative response to EGF stimulation, and colony formation ability in soft agar, indicating a conversion from a malignant phenotype to a benign phenotype.
  • Proteomic analysis revealed a significant down-regulation of a group of glycolytic enzymes in maspin-transfected cells.
  • This finding provides additional evidence of the tumor metastasis-suppressive activity of maspin and may indicate a new direction for future studies of the mechanism of maspin.
  • [MeSH-minor] Cell Differentiation. Cell Line, Tumor. Epidermal Growth Factor / pharmacology. Epithelial Cells. Esophageal Neoplasms. Humans. Neoplasm Metastasis / prevention & control. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 19090015.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serine Proteinase Inhibitors; 0 / Serpins; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


49. Foschini MP, Krausz T: Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential. Semin Diagn Pathol; 2010 Feb;27(1):77-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential.
  • The clinicopathologic spectrum ranges from benign to malignant but there are important differences as compared with those of their salivary counterpart.
  • In the breast, benign adenomyoepithelioma is recognized in addition to malignant one, whereas in the salivary gland a histologically similar tumor is designated as epithelial-myoepithelial carcinoma without a separate benign subgroup.
  • Mammary adenoid cystic carcinoma is a low-grade neoplasm compared with its salivary equivalent.
  • Most of these tumors are capable of differentiating along both epithelial and myoepithelial lines, but the amount of each lineage-component varies from case to case, contributing to diagnostic difficulties.
  • Another family of salivary gland-type mammary epithelial neoplasms is devoid of myoepithelial cells.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306833.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


50. Van Holsbeke C, Van Belle V, Leone FP, Guerriero S, Paladini D, Melis GB, Greggi S, Fischerova D, De Jonge E, Neven P, Bourne T, Valentin L, Van Huffel S, Timmerman D: Prospective external validation of the 'ovarian crescent sign' as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology. Ultrasound Obstet Gynecol; 2010 Jul;36(1):81-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective external validation of the 'ovarian crescent sign' as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology.
  • OBJECTIVE: To determine the sensitivity and specificity of the 'ovarian crescent sign' (OCS)-a rim of normal ovarian tissue seen adjacent to an ipsilateral adnexal mass-as a sonographic feature to discriminate between benign and malignant adnexal masses.
  • METHODS: The patients included were a subgroup of patients participating in the International Ovarian Tumor Analysis (IOTA) Phase 2 study, which is an international multicenter study.
  • The ability of the OCS to discriminate between borderline or invasively malignant vs. benign adnexal masses, as well as between invasively malignant vs. other (benign and borderline) tumors, was determined and compared with the performance of subjective evaluation of ultrasound findings by the ultrasound examiner.
  • RESULTS: The OCS was evaluated in 1377 adnexal masses from 12 centers, 938 (68%) masses being benign, 86 (6%) borderline, 305 (22%) primary invasive and 48 (3%) metastases.
  • The OCS was present in 398 (42%) of 938 benign masses, in 14 (16%) of 86 borderline tumors, in 18 (6%) of 305 primary invasive tumors (one malignant struma ovarii, one uterine clear cell adenocarcinoma and 16 epithelial carcinomas, i.e. four Stage I and 12 Stage II-IV) and in two (4%) of 48 ovarian metastases.
  • For discrimination between invasive vs. benign or borderline tumors, the sensitivity for absent OCS was 94%, the specificity was 40%, the LR+ was 1.58 and the LR- was 0.14.
  • However it is a poor discriminator between benign and malignant adnexal masses.
  • [MeSH-minor] Adnexal Diseases / ultrasonography. Diagnosis, Differential. Female. Humans. Neoplasm Staging. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 20217895.001).
  • [ISSN] 1469-0705
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


51. Serin IS, Tanriverdi F, Ata CD, Akalin H, Ozcelik B, Ozkul Y, Kelestimur F: GnRH-II mRNA expression in tumor tissue and peripheral blood mononuclear cells (PBMCs) in patients with malignant and benign ovarian tumors. Eur J Obstet Gynecol Reprod Biol; 2010 Mar;149(1):92-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GnRH-II mRNA expression in tumor tissue and peripheral blood mononuclear cells (PBMCs) in patients with malignant and benign ovarian tumors.
  • OBJECTIVE: To investigate the expression of the second form of GnRH (GnRH-II) in tumor tissue and peripheral blood mononuclear cells (PBMCs) in malignant and benign ovarian tumors in humans.
  • STUDY DESIGN: Sixty-six women were studied: 24 with epithelial ovarian carcinomas, 22 with benign ovarian tumors and 20 in the control group undergoing surgery.
  • Malignant, benign and normal ovarian tissue and PBMCs were obtained for measurement of GnRH-II mRNA levels using quantitative real-time RT-PCR.
  • RESULT(S): The expression of GnRH-II was found to be 1.5 times higher in malignant ovarian tumors compared with benign ovarian tumors and the control group in post-menopausal patients (P<0.01).
  • In the post-menopausal patient group with malignant ovarian tumors, there were significant positive correlations between serum FSH level and ovarian tissue GnRH-II mRNA expression (r=0.68; P=0.03), and serum LH level and ovarian tissue GnRH-II mRNA expression (r=0.71; P=0.02).
  • Controls, benign and malignant groups were similar in terms of GnRH-II expression in PBMCs in the pre- and post-menopausal periods.
  • These preliminary data suggest that local GnRH-II may participate in the regulation of ovarian tumor growth in post-menopausal women.
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Postmenopause / genetics. Postmenopause / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20018426.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / RNA, Messenger; 33515-09-2 / Gonadotropin-Releasing Hormone; 91097-16-4 / LHRH, His(5)-Trp(7)-Tyr(8)-
  •  go-up   go-down


52. Aitchison A, Warren A, Neal D, Rabbitts P: RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. Prostate; 2007 May 01;67(6):638-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues.
  • BACKGROUND: The RASSF1A gene is a tumor suppressor gene inactivated by hypermethylation in a very wide variety of malignant tumors including prostate cancer.
  • METHODS: In this study we have used laser capture microdissection to provide pure cell populations to investigate the methylation status of 16 CpG sites in the promoter region of this gene in prostatic intra-epithelial neoplasia, in histologically normal epithelial cells associated with these lesions and in epithelial cells from benign prostatic hyperplasia.
  • RESULTS: Unexpectedly, frequent methylation, detected by sequence analysis following bisulphite treatment, was observed in benign epithelium as well as in the lesions associated with prostatic intra-epithelial neoplasia and at high risk of cancer formation.
  • Fifty percent or more CpG sites were methylated in 7/14 prostatic intra-epithelial neoplasms, 8/11 histologically normal epithelial cells and 8/12 specimens of benign prostatic tissue.
  • CONCLUSION: These observations suggest that methylation of the RASSF1A gene is present in both pre-malignant and benign epithelia and suggests quantitation is required for it to be an effective marker of early prostate cancer.
  • [MeSH-major] DNA Methylation. Gene Silencing. Promoter Regions, Genetic. Prostatic Intraepithelial Neoplasia / genetics. Prostatic Neoplasms / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Biopsy, Needle. CpG Islands / genetics. DNA, Neoplasm / analysis. Humans. Lasers. Male. Microdissection. Middle Aged. Precancerous Conditions. Prostate / pathology. Sequence Analysis, DNA

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17342751.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0500966
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


53. Shekarkhar MJ, Tabei SZ, Kumar PV, Hashemi SB: Cytologic findings in calcifying epithelial odontogenic tumor: a case report. Acta Cytol; 2005 Sep-Oct;49(5):533-6
Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic findings in calcifying epithelial odontogenic tumor: a case report.
  • BACKGROUND: Calcifying epithelial odontogenic tumor (CEOT), or Pindborg's tumor, is a rare, benign, odontogenic neoplasm first described by Pindborg in 1955.
  • It is most commonly seen in the fourth and fifth decades of life, usually arises in the mandibular premolar-molar areas and accounts for approximately 1% of all intraosseous odontogenic tumors.
  • The fine needle aspiration (FNA) smears showed numerous calcifications; amorphous, eosinophilic material; and clusters of round epithelial cells embedded in a bloody background.
  • CONCLUSION: FNA findings of calcifying epithelial odontogenic tumor have been described rarely.
  • The clusters of epithelial cells with prominent nucleoli are mistaken for features of a malignant tumor.
  • [MeSH-major] Calcinosis / pathology. Epithelial Cells / pathology. Jaw Neoplasms / pathology. Maxillary Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology. Odontogenic Tumors / pathology. Palatal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334032.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Shibata K, Kajiyama H, Mizokami Y, Ino K, Nomura S, Mizutani S, Terauchi M, Kikkawa F: Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia. Gynecol Oncol; 2005 Jul;98(1):11-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
  • Glucose is transported into the cell via facilitative glucose transporters, which are known to be members of a supergene family.
  • The authors evaluated P-LAP and GLUT4 expression in benign, borderline, and malignant ovarian epithelia.
  • METHODS: Histologic sections of formalin-fixed, paraffin-embedded specimens from 11 patients with benign serous or mucinous cystadenomas, 14 patients with serous or mucinous borderline tumors, and 80 patients with epithelial-ovarian adenocarcinomas (29 serous, 17 endometrioid, 14 mucinous, and 20 clear cell adenocarcinomas) were stained for P-LAP and GLUT4 using each polyclonal antibody.
  • RESULTS: P-LAP immunoreactivity was detected in 2 of 11 benign cystadenomas.
  • None of the 11 benign ovarian tumors showed any immunoreactivity for GLUT4.
  • Seven of 14 borderline tumors demonstrated P-LAP immunoreactivity, while 5 of 14 borderline tumors demonstrated GLUT4 immunoreactivity.
  • CONCLUSIONS: P-LAP and GLUT4 are available not only for the evaluation of ovarian epithelial malignancy, but also as targets for molecular therapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Growth Processes / physiology. Cell Line, Tumor. Epithelium / enzymology. Epithelium / metabolism. Female. Glucose Transporter Type 4. Humans. Middle Aged. Neoplasm Invasiveness. Ovarian Diseases / enzymology. Ovarian Diseases / metabolism. Ovarian Diseases / pathology. Transfection

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15907336.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 4; 0 / Monosaccharide Transport Proteins; 0 / Muscle Proteins; 0 / SLC2A4 protein, human; EC 3.4.11.3 / Cystinyl Aminopeptidase; EC 3.4.11.3 / leucyl-cystinyl aminopeptidase
  •  go-up   go-down


55. Zhong Y, Wang L, Li T, Chen XM: Calcifying epithelial odontogenic tumour showing malignant transformation: a case report and review of the literature. Chin J Dent Res; 2010;13(2):157-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcifying epithelial odontogenic tumour showing malignant transformation: a case report and review of the literature.
  • Calcifying epithelial odontogenic tumour (CEOT) is a rare and benign odontogenic neoplasm that affects the jaws.
  • [MeSH-minor] Humans. Keratin-19 / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Odontogenic Tumors / pathology. Odontogenic Tumors / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21264368.001).
  • [ISSN] 1462-6446
  • [Journal-full-title] The Chinese journal of dental research : the official journal of the Scientific Section of the Chinese Stomatological Association (CSA)
  • [ISO-abbreviation] Chin J Dent Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-19; 0 / Ki-67 Antigen; Calcifying Epithelial Odontogenic Tumor
  •  go-up   go-down


56. Jin MS, Ha HJ, Baek HJ, Lee JC, Koh JS: Adenomyomatous hamartoma of lung mimicking benign mucinous tumor in fine needle aspiration biopsy: a case report. Acta Cytol; 2008 May-Jun;52(3):357-60
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomyomatous hamartoma of lung mimicking benign mucinous tumor in fine needle aspiration biopsy: a case report.
  • BACKGROUND: Typical cytologic features of pulmonary hamartoma (PH) are usually smears of hyaline cartilage, fibrous tissue, smooth muscle, adipocytic components and respiratory epithelium.
  • Cytologic features of adenomyomatous hamartoma, a special variant of PH, are not documented in the literature and are confused with epithelial neoplasm in the case of sparse stromal cellularity.
  • Fine needle aspiration biopsy (FNAB) revealed numerous mucinous epithelial cells presenting predominantly in cohesive cellular sheets that suggested benign mucinous epithelial lesion.
  • The patient underwent surgery for the tumor, and it was histologically proven to be an adenomyomatous hamartoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540306.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Mhawech-Fauceglia P, Saxena R, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R: Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. J Clin Pathol; 2007 Jun;60(6):709-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.
  • However, its expression in other tumour types is not fully explored.
  • AIMS AND METHODS: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections.
  • CONCLUSION: Despite its expression in a small subset of malignancies of epithelial origin, Pax-5 is still a good and reliable immunomarker in diagnosing B-NHL, HL and neuroendocrine carcinomas.
  • [MeSH-major] B-Cell-Specific Activator Protein / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Hodgkin Disease / diagnosis. Hodgkin Disease / metabolism. Humans. Immunoenzyme Techniques. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / metabolism. Neoplasm Proteins / metabolism. Protein Array Analysis / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2001 Jun;14(6):779-90 [11420047.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):687-92 [15832095.001]
  • [Cites] Trends Genet. 2002 Jan;18(1):41-7 [11750700.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1343-50 [12360049.001]
  • [Cites] Int Urol Nephrol. 2002-2003;34(4):495-501 [14577491.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):994-1000 [14608532.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1839-46 [15155532.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] Mech Dev. 1992 Nov;39(1-2):29-39 [1283313.001]
  • [Cites] Genomics. 1993 Dec;18(3):705-8 [7508415.001]
  • [Cites] C R Acad Sci III. 1995 Jan;318(1):57-66 [7757805.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5709-13 [7777574.001]
  • [Cites] Genes Dev. 1997 Feb 15;11(4):476-91 [9042861.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3197-204 [9120274.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5703-8 [9159136.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Clin Cancer Res. 1995 Feb;1(2):207-14 [9815975.001]
  • [Cites] Gen Physiol Biophys. 1998 Sep;17(3):211-24 [9834843.001]
  • [Cites] BJU Int. 1999 Jun;83(9):1039-44 [10368252.001]
  • [Cites] Nature. 1999 Oct 7;401(6753):556-62 [10524622.001]
  • [Cites] Int J Cancer. 2001 Aug 15;93(4):459-67 [11477548.001]
  • (PMID = 16837628.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / PAX5 protein, human
  • [Other-IDs] NLM/ PMC1955074
  •  go-up   go-down


58. Sugiyama M, Suzuki Y, Abe N, Mori T, Atomi Y: Management of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol; 2008;43(3):181-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of intraductal papillary mucinous neoplasm of the pancreas.
  • Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a distinct entity characterized by papillary proliferations of mucin-producing epithelial cells with excessive mucus production and cystic dilatation of the pancreatic ducts.
  • IPMNs are classified into main duct and branch duct types, based on the site of tumor involvement.
  • The postoperative 5-year survival rate is nearly 100% for benign tumors and noninvasive carcinoma, and approximately 60% for invasive carcinoma.
  • Surgical treatment is indicated for a branch duct IPMN with suspected malignancy (tumor diameter > or = 30 mm, mural nodules, dilated main pancreatic duct, or positive cytology) or positive symptoms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):441-5 [10685747.001]
  • [Cites] Surgery. 2000 May;127(5):536-44 [10819062.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2001-8 [9951854.001]
  • [Cites] Surgery. 1997 Sep;122(3):617-25 [9308621.001]
  • [Cites] AJR Am J Roentgenol. 2000 May;174(5):1403-8 [10789803.001]
  • [Cites] Gastrointest Endosc. 1998 Aug;48(2):164-71 [9717782.001]
  • [Cites] World J Surg. 2002 Sep;26(9):1166-9 [12045867.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2553-8 [12385438.001]
  • [Cites] World J Surg. 1998 Aug;22(8):874-8 [9673562.001]
  • [Cites] Am J Surg. 1996 Apr;171(4):427-31 [8604836.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):16-30 [10721804.001]
  • [Cites] Am J Gastroenterol. 1998 Feb;93(2):156-9 [9468232.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Apr;4(4):460-8 [16616351.001]
  • [Cites] Gastrointest Endosc. 1998 Jan;47(1):42-9 [9468422.001]
  • [Cites] Gastroenterology. 1996 Jun;110(6):1909-18 [8964418.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1759-64 [17686073.001]
  • [Cites] Radiology. 2000 Dec;217(3):757-64 [11110940.001]
  • [Cites] Pancreatology. 2002;2(5):484-90 [12378117.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Ann Surg. 1998 Nov;228(5):685-91 [9833807.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):376-81 [11260102.001]
  • [Cites] Am J Gastroenterol. 1993 Apr;88(4):564-9 [8385881.001]
  • [Cites] Am J Surg. 1998 May;175(5):426-32 [9600293.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1429-34 [11374678.001]
  • [Cites] Am J Surg. 2003 Mar;185(3):251-5 [12620565.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):34-43 [11781278.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):470-3 [10022648.001]
  • [Cites] J Gastroenterol. 2002;37(10):868-73 [12424574.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):1129-34 [11020896.001]
  • (PMID = 18373159.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 37
  •  go-up   go-down


59. Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, Calza S, Ravaggi A, Bandiera E, Pecorelli S, Santin AD: Overexpression of mammaglobin B in epithelial ovarian carcinomas. Gynecol Oncol; 2007 Jun;105(3):578-85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of mammaglobin B in epithelial ovarian carcinomas.
  • In order to evaluate its potential as a novel ovarian cancer biomarker, in this study we quantified and compared Mammaglobin B expression in various histologic types of epithelial ovarian carcinomas (EOC).
  • METHODS: Mammaglobin B expression was evaluated by real-time PCR and/or immunohistochemistry in fresh-frozen biopsies and paraffin-embedded tissues derived from a total of 137 patients including 69 primary EOC with different histologies, 28 serous papillary omental metastasis, 8 borderline tumors, 26 benign cystadenomas and 14 normal ovaries.
  • In contrast, normal human ovarian surface epithelium (HOSE) expressed negligible levels of Mammaglobin B mRNA (EOC versus HOSE, p<0.01).
  • Although Mammaglobin B gene expression levels were higher in endometrioid, mucinous and undifferentiated tumors when compared to serous papillary tumors, clear cell tumors and those with mixed histology, these differences were not statistically significant.
  • In agreement with real-time PCR results, EOC were found to express significantly higher levels of Mammaglobin B protein when compared to normal ovaries and benign cystadenomas (p<0.01).
  • [MeSH-major] Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / immunology. Uteroglobin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Cell Line, Tumor. Female. Gene Expression. Humans. Immunohistochemistry. Mammaglobin B. Middle Aged. Myelin Proteins. Polymerase Chain Reaction. Proteolipids. Secretoglobins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343903.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin B; 0 / Myelin Proteins; 0 / Neoplasm Proteins; 0 / Proteolipids; 0 / SCGB2A1 protein, human; 0 / Secretoglobins; 9060-09-7 / Uteroglobin
  •  go-up   go-down


60. Chechlinska M, Kaminska J, Markowska J, Kramar A, Steffen J: Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination. Int J Biol Markers; 2007 Jul-Sep;22(3):172-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination.
  • This study aimed to assess the potential value of peritoneal fluid cytokine examination for the differential diagnosis of ovarian tumors and for evaluating residual or recurrent disease after treatment.
  • The cytokines that are commonly elevated in ovarian cancer, VEGF, IL-6, bFGF, IL-8 and M-CSF, and a reference ovarian tumor marker, CA 125, were measured in peritoneal fluids of 53 previously untreated patients with epithelial ovarian cancer, 18 ovarian cancer patients after surgical treatment and chemotherapy, and 17 patients with benign epithelial ovarian tumors.
  • Ovarian cancer peritoneal fluids, as compared to peritoneal fluids of patients with benign ovarian tumors, contained significantly higher concentrations of IL-6, VEGF and CA 125, and significantly lower concentrations of bFGF and M-CSF, but only the levels of IL-6 and VEGF were significantly higher in peritoneal fluids of stage I and II ovarian cancer patients than of patients with benign ovarian conditions.
  • IL-6 at the cutoff level of 400 pg/mL discriminated benign and malignant ovarian tumors with 92% sensitivity and 60% specificity, while VEGF at the cutoff of 400 pg/mL had 90% sensitivity and 80% specificity.
  • IL-6 and VEGF measurements in peritoneal fluids might be useful for the differential diagnosis of malignant and benign ovarian conditions, but not for residual or recurrent disease examination.
  • [MeSH-major] Ascitic Fluid / immunology. Cytokines / analysis. Neoplasm Recurrence, Local / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biomarkers, Tumor / blood. CA-125 Antigen / analysis. CA-125 Antigen / biosynthesis. CA-125 Antigen / blood. Diagnosis, Differential. Female. Humans. Interleukin-6 / immunology. Middle Aged. Neoplasm Staging. Neoplasm, Residual. Vascular Endothelial Growth Factors / analysis. Vascular Endothelial Growth Factors / blood

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922459.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Cytokines; 0 / Interleukin-6; 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


61. Deboni MC, Naclério-Homem Mda G, Pinto Junior DS, Traina AA, Cavalcanti MG: Clinical, radiological and histological features of calcifying epithelial odontogenic tumor: case report. Braz Dent J; 2006;17(2):171-4
Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, radiological and histological features of calcifying epithelial odontogenic tumor: case report.
  • The calcifying epithelial odontogenic tumor (CEOT) is a rare benign odontogenic neoplasm that accounts for approximately 1% of all odontogenic tumors.
  • A case of an advanced CEOT associated with an impacted right second molar in the mandible of a young black female patient is presented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16924348.001).
  • [ISSN] 0103-6440
  • [Journal-full-title] Brazilian dental journal
  • [ISO-abbreviation] Braz Dent J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  •  go-up   go-down


62. Laskin WB, Fetsch JF, Lasota J, Miettinen M: Benign epithelioid peripheral nerve sheath tumors of the soft tissues: clinicopathologic spectrum of 33 cases. Am J Surg Pathol; 2005 Jan;29(1):39-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign epithelioid peripheral nerve sheath tumors of the soft tissues: clinicopathologic spectrum of 33 cases.
  • Benign epithelioid peripheral nerve sheath tumors (BEPNSTs) have not been fully characterized, and their relationship to conventional schwannoma and neurofibroma has not been satisfactorily established.
  • The tumors were predominantly dermal/subcutaneous in location (85%) and involved the lower limb (n=15), upper limb (n=11), trunk (n=4), and head/neck (n=3).
  • Microscopically, the tumors were generally well-circumscribed, uninodular, or multinodular masses.
  • Tumors consisted of trabeculae, loosely arranged nodules, and cohesive nests of epithelioid tumor cells immersed in collagenous, myxohyaline, or chiefly myxoid stroma.
  • A bland spindled cell component comprising 5% to 40% of the tumor was noted in 15 cases.
  • Immunohistochemical reactivity for Schwann cell-related markers in tumor cells included S-100 protein (20 of 20 cases), collagen type IV (10 of 10), laminin (8 of 8), nerve growth factor receptor, p75(7 of 8), CD57 (6 of 9), and glial fibrillary acidic protein (8 of 15).
  • Anti-epithelial membrane antigen highlighted perineurial cells in 9 of the 11 encapsulated tumors.
  • Anti-neurofilament protein did not identify intralesional neuraxons in the 10 tumors evaluated.
  • Eighteen tumors were subtyped as epithelioid neurofibromas.
  • The remaining 15 cases showed some histologic features suggestive of schwannoma, but their uniform cellularity, absence of nuclear palisading, and presence of a significant CD34-positive spindled cell population in 5 cases led to their classification as "BEPNST of indeterminate histogenesis."
  • Follow-up for 18 patients (median interval, 13.5 years), including 4 patients with tumors exhibiting cytologic atypia, revealed a nondestructive recurrence or persistent disease in 3 patients whose tumors lacked atypia, but no evidence of metastatic spread or tumor-related death.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Child. Child, Preschool. DNA, Neoplasm / analysis. Female. Humans. Immunoenzyme Techniques. Loss of Heterozygosity. Male. Middle Aged. Mitotic Index. Neurofibromin 1 / genetics. Neurofibromin 1 / metabolism. Neurofibromin 2 / genetics. Neurofibromin 2 / metabolism. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613855.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Neurofibromin 1; 0 / Neurofibromin 2
  •  go-up   go-down


63. Bleiweiss IJ, Nagi CS, Jaffer S: Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. J Clin Oncol; 2006 May 1;24(13):2013-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma.
  • Iatrogenic epithelial cell displacement and benign transport of breast epithelial cells into axillary lymph nodes are recently described phenomena.
  • We report 25 cases in which these factors probably resulted in benign epithelial cells in axillary SLNs (ie, false positivity).
  • METHODS: We reviewed 25 cases of CK-positive SLNs in which the epithelial cells had histologic and IHC characteristics different from their respective patients' underlying breast carcinomas.
  • RESULTS: In all cases, the cytologic features of the epithelial cells in the SLNs were benign, and 22 matched those of corresponding intraductal papillomas that were involved by or were separate from the DCIS in the original cores or surgical biopsies.
  • Fifteen cases were pure DCIS; most invasive tumors were smaller than 1.0 cm.
  • In six carcinomas (DCIS) showing strong Her-2/neu staining, the corresponding epithelial cells in the SLNs were negative.
  • In 13 tumors that were strongly and uniformly positive for estrogen receptor (ER), the cytokeratin-positive cells in the SLNs were negative for ER.
  • Nineteen cases showed benign epithelial cell displacement at the biopsy site.
  • CONCLUSION: Epithelial cells in SLNs may result from transport of displaced cells, usually originating in intraductal papillomas.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Axilla. Cell Movement. Epithelial Cells / pathology. False Positive Reactions. Female. Humans. Immunohistochemistry. Keratins / analysis. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 May 1;24(13):1978-9 [16606969.001]
  • (PMID = 16606970.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


64. Karanikolas BD, Figueiredo ML, Wu L: Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol Cancer Res; 2009 Sep;7(9):1456-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line.
  • Although this correlation means EZH2 could prove valuable as a biomarker in clinical settings, the question remains whether EZH2 is actually responsible for the initiation of these more aggressive tumor types.
  • In this study, EZH2-mediated neoplastic transformation of the normal prostate epithelial cell line benign prostate hyperplasia 1 (BPH1) was confirmed by in vivo tumor growth and in vitro colony formation.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Matrix Biol. 1999 Oct;18(5):455-67 [10601733.001]
  • [Cites] BJU Int. 2000 May;85(7):932-44 [10792179.001]
  • [Cites] Genes Dev. 2001 Feb 1;15(3):267-85 [11159908.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):551-7 [11208850.001]
  • [Cites] Curr Opin Genet Dev. 2001 Apr;11(2):175-81 [11250141.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):950-8 [11298590.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8143-9 [11719443.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2830-5 [11880635.001]
  • [Cites] Nature. 2002 Oct 10;419(6907):624-9 [12374981.001]
  • [Cites] Cell. 2002 Oct 18;111(2):197-208 [12408864.001]
  • [Cites] Science. 2002 Nov 1;298(5595):1039-43 [12351676.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):473-85 [12492490.001]
  • [Cites] Cell. 2003 Mar 7;112(5):599-606 [12628181.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1981-9 [12702592.001]
  • [Cites] J Natl Cancer Inst. 2003 May 7;95(9):661-8 [12734317.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):459-65 [12778136.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7841-6 [12799464.001]
  • [Cites] Mol Biol Cell. 2003 Jul;14(7):2728-43 [12857860.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 [14500907.001]
  • [Cites] EMBO J. 2003 Oct 15;22(20):5323-35 [14532106.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):13-25 [14689577.001]
  • [Cites] Neoplasia. 2003 Nov-Dec;5(6):481-8 [14965441.001]
  • [Cites] Curr Opin Genet Dev. 2004 Apr;14(2):155-64 [15196462.001]
  • [Cites] Oncogene. 2004 Jun 17;23(28):4930-7 [15077161.001]
  • [Cites] Mol Cell. 2004 Jul 2;15(1):57-67 [15225548.001]
  • [Cites] Genes Dev. 2004 Jul 1;18(13):1592-605 [15231737.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5759-69 [15208672.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(3):148-54 [2544306.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1721-32 [7906858.001]
  • [Cites] Nucleic Acids Res. 1995 Feb 25;23(4):628-33 [7899083.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24 [7535634.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):3219-32 [9214638.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3586-95 [9584199.001]
  • [Cites] J Virol. 1998 Oct;72(10):8150-7 [9733856.001]
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] Anal Biochem. 1999 May 15;270(1):41-9 [10328763.001]
  • [Cites] Exp Gerontol. 1999 Apr;34(2):275-87 [10363793.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):1199-208 [15536069.001]
  • [Cites] DNA Cell Biol. 2005 Feb;24(2):117-25 [15699631.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 10;102(19):6942-7 [15860580.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):22437-44 [15817459.001]
  • [Cites] Oncogene. 2005 Sep 15;24(41):6269-80 [16007202.001]
  • [Cites] Science. 2005 Oct 14;310(5746):306-10 [16224021.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7465-74 [16288293.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):268-73 [16330673.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1168-74 [16489070.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):639-45 [16575874.001]
  • [Cites] Methods Enzymol. 2006;407:660-76 [16757360.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24790-802 [16766534.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14122-7 [16959882.001]
  • [Cites] J Cell Physiol. 2007 Jan;210(1):183-91 [16998811.001]
  • [Cites] Genes Dev. 2007 Jan 1;21(1):49-54 [17210787.001]
  • [Cites] Nat Cell Biol. 2007 Mar;9(3):347-53 [17277772.001]
  • [Cites] Prostate. 2007 Apr 1;67(5):547-56 [17252556.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]
  • [Cites] Mol Carcinog. 2008 Jun;47(6):466-77 [18058808.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7828-37 [18829538.001]
  • [Cites] Science. 2008 Dec 12;322(5908):1695-9 [19008416.001]
  • [Cites] J Cutan Pathol. 2007 Aug;34(8):597-600 [17640228.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2153-61 [17583576.001]
  • [Cites] Cancer Cell. 2007 Nov;12(5):419-31 [17996646.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10657-63 [18006806.001]
  • [Cites] Int J Cancer. 2008 Feb 1;122(3):595-602 [17943722.001]
  • [Cites] Prostate. 2008 Feb 15;68(3):255-63 [18095286.001]
  • [Cites] Dis Markers. 2008;24(3):157-65 [18334737.001]
  • (PMID = 19723877.001).
  • [ISSN] 1557-3125
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA092131-08; United States / NCI NIH HHS / CA / P50 CA092131; United States / NCI NIH HHS / CA / P30 CA016042; United States / NIAID NIH HHS / AI / P30 AI028697; United States / NCI NIH HHS / CA / R01 CA101904-07; United States / NCI NIH HHS / CA / R01 CA101904; United States / NCI NIH HHS / CA / CA101904-07
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Transcription Factors; 147336-22-9 / Green Fluorescent Proteins; EC 2.1.1.- / Protein Methyltransferases; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Polycomb Repressive Complex 2; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ NIHMS159142; NLM/ PMC2794652
  •  go-up   go-down


65. Arts HJ, de Jong S, Hollema H, Ten Hoor KA, de Vries EG, van der Zee AG: Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors. Int J Oncol; 2005 Feb;26(2):379-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors.
  • In this study Fas and FasL levels in cyst fluids and sera of patients with benign, borderline and malignant ovarian tumors and in corresponding tumors are determined.
  • Fas and FasL were determinded by ELISA and immunohistochemistry in 30 patients with benign, 5 patients with borderline and 24 patients with malignant epithelial ovarian tumors.
  • In malignant cyst fluids, median Fas levels where higher compared to benign cyst fluids (p<0.01).
  • FasL immunostaining was more frequent in malignant ovarian tumors (p=0.002).
  • High expression of both Fas and FasL, in malignant ovarian tumors present Fas/FasL as an interesting route to explore for innovative cancer therapy.
  • [MeSH-minor] Blotting, Western. Drug Resistance, Neoplasm. Enzyme-Linked Immunosorbent Assay. Fas Ligand Protein. Female. Humans. Immunohistochemistry. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15645122.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins
  •  go-up   go-down


66. Minelli A, Ronquist G, Carlsson L, Mearini E, Nilsson O, Larsson A: Antiprostasome antibody titres in benign and malignant prostate disease. Anticancer Res; 2005 Nov-Dec;25(6C):4399-402
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiprostasome antibody titres in benign and malignant prostate disease.
  • BACKGROUND: Prostasomes are secretory granules synthesized, stored and secreted by normal and neoplastic human prostate epithelial cells and by prostate cancer metastasis.
  • MATERIALS AND METHODS: An antiprostasome antibody ELISA was developed and used to measure serum antibody titres in 81 males with prostate cancer or benign prostate hyperplasia.
  • RESULTS: Patients with biopsy-verified prostate cancer had significantly higher antibody titres [p = 0.019 for the dominant tumour expression (first Gleason parameter) and p = 0.022 for the dominant and non-dominant form (first and second Gleason parameters)] than individuals with benign prostate hyperplasia or other benign prostate disorders.
  • [MeSH-major] Antibodies, Neoplasm / blood. Prostatic Hyperplasia / immunology. Prostatic Neoplasms / immunology. Prostatitis / immunology. Secretory Vesicles / immunology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334115.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


67. Kothandaraman N, Bajic VB, Brendan PN, Huak CY, Keow PB, Razvi K, Salto-Tellez M, Choolani M: E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer. BMC Cancer; 2010;10:64
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer.
  • BACKGROUND: Ovarian epithelial cancer (OEC) usually presents in the later stages of the disease.
  • Factors, especially those associated with cell-cycle genes, affecting the genesis and tumour progression for ovarian cancer are largely unknown.
  • Our hypothesis was supported by our tissue array experiments that showed E2F5 expression only in OEC samples but not in normal and benign tissues, and by significantly positively biased expression in serum samples done using western blotting studies.
  • RESULTS: Analysis of clinical cases shows that of the E2F5 status is characteristic for a different population group than one covered by CA125, a conventional OEC biomarker.
  • E2F5 used in different combinations with CA125 for distinguishing malignant cyst from benign cyst shows that the presence of CA125 or E2F5 increases sensitivity of OEC detection to 97.9% (an increase from 87.5% if only CA125 is used) and, more importantly, the presence of both CA125 and E2F5 increases specificity of OEC to 72.5% (an increase from 55% if only CA125 is used).
  • Furthermore, detection of malignancy status in 86 cases (38 benign, 48 early and late OEC) shows that the use of E2F5 status in combination with other clinical characteristics allows for an improved detection of malignant cases with sensitivity, specificity, F-measure and accuracy of 97.92%, 97.37%, 97.92% and 97.67%, respectively.
  • [MeSH-minor] Adult. Aged. Algorithms. Biomarkers, Tumor / metabolism. CA-125 Antigen / biosynthesis. Disease Progression. Female. Humans. Middle Aged. Neoplasm Metastasis. Reproducibility of Results. Sensitivity and Specificity


68. Zhang Z, Jia L, Feng Y, Zheng W: Overexpression of follicle-stimulating hormone receptor facilitates the development of ovarian epithelial cancer. Cancer Lett; 2009 Jun 8;278(1):56-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of follicle-stimulating hormone receptor facilitates the development of ovarian epithelial cancer.
  • We previously showed that the expressing level of FSH receptor (FSHR) increased from ovarian epithelial inclusions (OEIs) to benign ovarian epithelial tumors (OETs) and to borderline OETs, whereas FSHR levels decreased with an increase in carcinoma grade.
  • [MeSH-minor] Blotting, Western. Cell Cycle / drug effects. Cell Line, Tumor. DNA Primers. Epithelial Cells / pathology. Female. Humans. Neoplasm Invasiveness. Polymerase Chain Reaction. RNA, Neoplasm / genetics. Repressor Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction. Transfection


69. Qiao YH, Cheng J, Guo RX: [Expression of phosphorylated protein kinase B and PTEN protein in ovarian epithelial cancer]. Zhonghua Fu Chan Ke Za Zhi; 2007 May;42(5):325-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of phosphorylated protein kinase B and PTEN protein in ovarian epithelial cancer].
  • OBJECTIVE: To analyze the expression of phosphorylated protein kinase B (pAKT) and PTEN protein in ovarian epithelial cancer and to investigate the correlations between their expression and prognosis of ovarian epithelial cancers.
  • METHODS: Expression of pAKT and PTEN in 12 normal ovarian tissues, 20 benign tumors, 12 borderline tumors and 80 cases of ovarian epithelial cancers were detected by immunohistochemical method, and their correlations were analyzed.
  • RESULTS: The positive expression of pAKT in normal ovarian and benign tumor tissues were significantly lower than that in ovarian epithelial cancers (8%, 10% vs 55%; P < 0.01), respectively.
  • However, loss of PTEN expression in ovarian epithelial cancers was significantly higher than that in normal ovarian and benign tumor tissues, and the positive rate of PTEN expression were respectively, 45%, 100%, and 80% (P < 0.01).
  • Loss of PTEN expression is the independent risk factor of poor prognosis in patients with ovarian epithelial cancers.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Phosphorylation. Prognosis. Survival Analysis. Tumor Suppressor Proteins / biosynthesis


70. Szczepulska-Wójcik E, Langfort R, Roszkowski-Sliz K: [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Pneumonol Alergol Pol; 2007;75(1):57-69
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
  • INTRODUCTION: Histopathological diagnosis of malignant mesothelioma (MM) and differentiating it from tumors infiltrating the pleura is very difficult.
  • Distinguishing benign reactive mesothelial cell proliferation from MM also presents problems.
  • The objective of this study was to evaluate the significance of selected immunohistochemical stains in differentiating MM from non-small cell lung cancers infiltrating the pleura and from benign reactive mesothelial cell proliferation.
  • MATERIAL AND METHODS: The material encompassed 86 cases of MM, 54 cases of NSCLC infiltrating the pleura, and 43 cases of benign reactive mesothelial cell proliferation.
  • It included broad-spectrum antibodies to cytokeratins (CKAE1/AE3, CKMNF116), vimentin, epithelial membrane antigen (EMA), mesothelial cells (HBME1, CK5/6, calretinin), adenocarcinoma cells (BerEp4, B72.3, CEA, TTF1), antibodies enabling the assessment of proliferation (Mib1) and cell-cycle regulating proteins (p53).
  • Benign reactive mesothelial cell proliferation: Protein p53 was present in 9.3% of cases, whereas no positive staining for EMA was found.
  • In the diagnosis of spindle-cell pleural tumors and the fibrous form of MM and benign reactive mesothelial cell proliferation , markers of mesothelial cells are noncontributory.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / analysis. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / pathology. Mesothelioma / pathology. Neoplasm Proteins / analysis. Neoplasms, Mesothelial / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / analysis. Diagnosis, Differential. Epithelium / chemistry. Epithelium / pathology. Female. Humans. Hyperplasia / pathology. Immunohistochemistry. Lung / chemistry. Lung / pathology. Male. Middle Aged. Pleura / chemistry. Pleura / pathology. Pleural Effusion / chemistry. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541913.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


71. Chen XD, Shi HY, Zhang XF: [Clinicopathologic analysis of 102 cases of mixed epithelial and mesenchymal tumors of the uterus]. Zhonghua Fu Chan Ke Za Zhi; 2007 Apr;42(4):219-21
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic analysis of 102 cases of mixed epithelial and mesenchymal tumors of the uterus].
  • OBJECTIVE: To study the clinical and pathologic features, histological criteria and pathologic factors contributing to diagnosis of mixed epithelial and mesenchymal tumors (mixed müllerian tumors, MMT) of the uterus.
  • Benign MMT usually presented as exophytic polypoid masses extending into the uterine cavity or protruding through the external os, often broad-based, lobulated and papillary.
  • It was hard to distinguish low-grade malignant MMT from the benign ones by gross appearance.
  • Histologically, MMT showed a biphasic differentiation of mesenchymal and epithelial components.
  • MMT were classified according to whether these elements were benign or malignant.
  • Recurrent tumors were almost always confined to the original site.
  • CONCLUSIONS: Uterine MMT tumors according to WHO diagnostic criteria are not rare.
  • The recurrent adenofibromas may be a kind of borderline tumors with benign appearances and malignant behavior.
  • [MeSH-major] Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adenofibroma / pathology. Adenomyoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Epithelium / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17631758.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


72. Ota T, Gilks CB, Longacre T, Leung PC, Auersperg N: HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. Reprod Sci; 2007 Sep;14(6):605-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
  • Interrelationships between HOXA7 expression and ovarian cancer progression are investigated by cDNA array and by immunohistochemistry of normal ovaries and 538 epithelial ovarian tumor microarrays.
  • HOXA7 mRNA expression was higher in carcinomas than in benign tumors.
  • HOXA7 protein was absent in normal surface epithelium but appeared in metaplastic regions.
  • There were significant associations of strong HOXA7 staining of stroma and tumor nuclei with the clear cell histotype (stroma: P = .0022, nuclei: P = .0003) and of weak/absent staining with serous carcinomas.
  • Tumor E-cadherin expression correlated significantly with HOX7 staining in stroma (P = .0002) but not within tumors.
  • HOXA7 staining of tumor cell nuclei is correlated significantly with improved disease-specific survival (P = .0104), which is suggestive of the biological and potentially clinical importance of subcellular HOXA7 localization.
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemistry. Adenocarcinoma, Mucinous / chemistry. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / chemistry. Cell Differentiation. Cystadenocarcinoma, Serous / chemistry. Homeodomain Proteins / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Cadherins / analysis. Cell Nucleus / chemistry. Cluster Analysis. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Metaplasia. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. Stromal Cells / chemistry. Stromal Cells / pathology. Tissue Array Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17959889.001).
  • [ISSN] 1933-7205
  • [Journal-full-title] Reproductive sciences (Thousand Oaks, Calif.)
  • [ISO-abbreviation] Reprod Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / HOXA7 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


73. Kuźbicki L, Gajo B, Chwirot BW: Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions. Melanoma Res; 2006 Jun;16(3):235-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions.
  • It is thought that enhanced expression of lysosome-associated membrane protein-1 in tumour cells may promote invasion by influencing both adhesion to extracellular matrix and perhaps also binding to endothelial cells.
  • The present study was aimed at examining levels of lysosome-associated membrane protein-1 in human melanomas and benign pigmented lesions to evaluate whether this protein might be considered a potential molecular marker of melanoma progression.
  • The expression of lysosome-associated membrane protein-1 was for the first time determined immunohistochemically in formalin-fixed paraffin-embedded specimens comprising 42 primary cutaneous melanomas, 15 lymph node melanoma metastases (11 correlated with primary tumours), three melanoma recurrences (correlated with both primary and metastatic melanomas), 27 nevi and four epithelial tumours (two seborrhoeic keratoses and two basal cell carcinomas).
  • [MeSH-minor] Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunohistochemistry. Lymphatic Metastasis. Neoplasm Recurrence, Local / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16718270.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lysosomal-Associated Membrane Protein 1
  •  go-up   go-down


74. Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, Tamura R, Timor-Tritsch I, Schwartz PE: The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol; 2005 Apr;192(4):1214-21; discussion 1221-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.
  • OBJECTIVE: Epithelial ovarian cancer kills more women than all other gynecologic malignancies combined because of our inability to detect early-stage disease.
  • Ultrasonography has demonstrated usefulness in the detection of ovarian cancer in asymptomatic women, but its value for the detection of early-stage epithelial ovarian cancer in women of increased risk is uncertain.
  • We examined the usefulness of sonography in the detection of early-stage epithelial ovarian cancer in asymptomatic high-risk women who participated in the National Ovarian Cancer Early Detection Program.
  • Increased risk includes women with at least 1 affected first-degree relative with ovarian cancer; a personal history of breast, ovarian, or colon cancer; > or =1 affected first- and second-degree relatives with breast and or ovarian cancer; inheritance of a breast cancer mutation from an affected family member, or membership within a recognized cancer syndrome.
  • A total of 98 women with persistent adnexal masses were identified, and 49 invasive surgical procedures were performed that diagnosed 37 benign ovarian tumors and 12 gynecologic malignancies.
  • The detected malignancies were fallopian tube carcinoma (stage IIIC; n = 4 women), primary peritoneal carcinoma (n = 4 women; stage IIIA, 1 woman; stage IIIB, 2 women; stage IIIC, 1 woman), epithelial ovarian cancer (stages IIIA and IIIB; n = 2 women), and endometrial adenocarcinoma (stage IA; n = 2 women).
  • CONCLUSION: This study demonstrates the limited value of diagnostic ultrasound examination as an independent modality for the detection of early-stage epithelial ovarian cancer in asymptomatic women who are at increased risk for disease.
  • [MeSH-major] Mass Screening / methods. Neoplasms, Glandular and Epithelial / pathology. Neoplasms, Glandular and Epithelial / ultrasonography. Ovarian Neoplasms / pathology. Ovarian Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Age Distribution. Aged. Cohort Studies. Female. Humans. Immunohistochemistry. Incidence. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Ultrasonography, Doppler, Color

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846205.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA83639; United States / NCI NIH HHS / CA / R01 CA01015; United States / NCI NIH HHS / CA / R01 CA82562; United States / NCI NIH HHS / CA / R01 CA89503; United States / NCI NIH HHS / CA / UO1CA85133
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


75. Chakhachiro ZI, Zaatari G: Solid-pseudopapillary neoplasm: a pancreatic enigma. Arch Pathol Lab Med; 2009 Dec;133(12):1989-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid-pseudopapillary neoplasm: a pancreatic enigma.
  • Solid-pseudopapillary neoplasm of the pancreas is a relatively uncommon tumor.
  • Although previously considered benign, this tumor is currently considered a low-grade malignant epithelial neoplasm with low metastatic rate and high overall survival.
  • Despite the characterization of the morphologic and molecular features of this enigmatic neoplasm, more work is needed to uncover its cell of origin and true histogenesis.
  • [MeSH-minor] Biomarkers, Tumor / genetics. Female. Genetic Predisposition to Disease. Humans. Mutation. Treatment Outcome. beta Catenin / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961258.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / beta Catenin
  • [Number-of-references] 30
  •  go-up   go-down


76. Poli Neto OB, Candido Dos Reis FJ, Zambelli Ramalho LN, Nogueira AA, de Andrade JM: p63 expression in epithelial ovarian tumors. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):152-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 expression in epithelial ovarian tumors.
  • The p63 is a homologue gene of the tumor suppressor p53. p63 appears to be important for the development and differentiation of reproductive epithelium and interacts with p53 in human tumorigenesis.
  • This study presents the immunoexpression of the p63 in benign and malignant epithelial ovarian tumors.
  • We evaluated the p63 immunoexpression in 91 ovarian benign cystadenomas (29 mucinous and 62 serous) and in 29 ovarian malignant tumors (3 mucinous borderline, 3 serous borderline, 17 serous carcinomas, 2 endometrioid, 2 undifferentiated, 1 mucinous, and 1 clear-cell carcinoma) using a monoclonal antibody clone 4A4 (1:200), which recognizes all p63 variants.
  • The tumors were considered p63 positive if 5% or more cells presented nuclear immunostaining.
  • We observed 85.7% of positivity in benign tumors, 50% in borderline tumors, and 8.7% in invasive ovarian cancer (P < .0001).
  • The benign serous cystadenomas were positive in 91.9% of cases and benign mucinous cystadenomas in 72.4% (P= .02).
  • These data suggests an important role of p63 in the control of ovarian epithelium behavior.
  • The p63 may be involved in the development of benign and malignant epithelial ovarian tumors.
  • [MeSH-minor] Adult. Age Factors. Biomarkers, Tumor / analysis. Biopsy, Needle. Cohort Studies. DNA-Binding Proteins. Female. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Probability. Prognosis. Risk Assessment. Sensitivity and Specificity. Tissue Culture Techniques. Transcription Factors. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445626.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


77. Ansieau S, Caron de Fromentel C, Bastid J, Morel AP, Puisieux A: [Role of the epithelial-mesenchymal transition during tumor progression]. Bull Cancer; 2010 Jan;97(1):7-15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of the epithelial-mesenchymal transition during tumor progression].
  • [Transliterated title] Rôle de la transition épithéliomésenchymateuse dans la progression tumorale.
  • The epithelial-mesenchymal transition (EMT) is a morphogenetic program that converts epithelial into mesenchymal cells during the embryonic development.
  • This mechanism is frequently reactivated during tumor progression and provides cells with motility and invasive capabilities favoring the metastatic dissemination from epithelial tumors.
  • Various EMT-inducing transcription factors, such as the TWIST proteins, were also shown to inhibit oncogene-induced fail-safe programs (senescence and apoptosis), thereby promoting the progression from benign to malignant stages.
  • Altogether, these observations suggest that EMT could play an important role in favoring both tumor development and metastatic dissemination.
  • [MeSH-major] Cell Transdifferentiation / physiology. Epithelial Cells / pathology. Mesoderm / pathology. Neoplasm Metastasis / pathology
  • [MeSH-minor] Animals. Cell Aging / physiology. Cell Movement / physiology. Disease Progression. Humans. Mice. Neoplasm Invasiveness. Neoplastic Stem Cells / physiology. Signal Transduction / physiology. Transcription Factors / physiology. Transcriptional Activation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026450.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Transcription Factors
  •  go-up   go-down


78. Nakano K, Siar CH, Tsujigiwa H, Nagatsuka H, Nagai N, Kawakami T: Notch signaling in benign and malignant ameloblastic neoplasms. Eur J Med Res; 2008 Oct 27;13(10):476-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch signaling in benign and malignant ameloblastic neoplasms.
  • METHODS: We examined Notch1 peptide and its gene (mRNA) in an ameloblastoma (case 1: 27-year-old female, right mandibular tumor) and an ameloblastic carcinoma (case 2: 93-year-old female, right mandibular tumor), using immunohistochemistry (IHC) and in situ hybridization (ISH) techniques.
  • RESULTS: Notch1 intracellular domain (NICD) positive products were observed in the cells at the peripheral layer of most proliferating epithelial tumor nests in case 1.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Expression. Humans. Immunohistochemistry. In Situ Hybridization. Protein Structure, Tertiary. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19008176.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / NOTCH1 protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptor, Notch1
  •  go-up   go-down


79. Nakaguro M, Suzuki Y, Ichihara S, Kobayashi TK, Ono K: Epithelial inclusion cyst arising in an intramammary lymph node: case report with cytologic findings. Diagn Cytopathol; 2009 Mar;37(3):199-202
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial inclusion cyst arising in an intramammary lymph node: case report with cytologic findings.
  • The occurrence of epithelial inclusion cysts (EIC) in axillary lymph nodes is a rare but well recognized entity, arising either from direct implantation or from embryonal rests.
  • Here, we describe a case of an EIC arising in an intramammary lymph node of a 37-year-old woman.
  • On FNA, the EIC arising in an intramammary lymph node was characterized by mature lymphocytes, squamous epithelial cells, and keratinizing material.
  • Contrary to these more sinister diagnoses, EIC arising in an intramammary lymph node is a benign condition.
  • As this rare lesion sometimes mimics a neoplasm both clinically and radiographically, awareness of this entity is important to prevent over treatment.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19177497.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Bello IO, Alanen K, Slootweg PJ, Salo T: Alpha-smooth muscle actin within epithelial islands is predictive of ameloblastic carcinoma. Oral Oncol; 2009 Sep;45(9):760-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-smooth muscle actin within epithelial islands is predictive of ameloblastic carcinoma.
  • Ameloblastoma is the most common clinically significant odontogenic tumor.
  • It is considered benign but locally invasive and associated with variable clinico-pathological behavior.
  • Ameloblastic carcinoma is a malignant tumor having features of ameloblastoma in addition to cytologic atypia with or without metastasis.
  • The aim of this study was to examine which epithelial and stromal markers are predictive of histologically diagnosed ameloblastic carcinoma and can sufficiently differentiate it from solid/multicystic ameloblastoma (SA).
  • We examined immunohistochemically Ki-67, epithelial membrane antigen (EMA), alpha-smooth muscle actin (alpha-SMA), calponin, p63 and DNA content using image (ICM) and flow cytometry (FCM) in three ameloblastic carcinomas and up to 18 SAs.
  • Expression of alpha-SMA was consistently obtained within the epithelial island cells of ameloblastic carcinoma and not in SA, although the marker was well expressed in the stroma of both lesions.
  • We therefore conclude that the presence of alpha-SMA within the epithelial islands is highly predictive of ameloblastic carcinoma.
  • [MeSH-major] Ameloblastoma / pathology. Carcinoma / pathology. Mandibular Neoplasms / pathology. Maxillary Neoplasms / pathology. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Ameloblastic carcinoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19150605.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / CKAP4 protein, human; 0 / Calcium-Binding Proteins; 0 / Ki-67 Antigen; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Mucin-1; 0 / Neoplasm Proteins; 0 / calponin
  •  go-up   go-down


81. Zhao C, Annamalai L, Guo C, Kothandaraman N, Koh SC, Zhang H, Biswas A, Choolani M: Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. Neoplasia; 2007 Jan;9(1):1-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer.
  • OBJECTIVE: This study was conducted to evaluate the prognostic significance of haptoglobin levels in the overall survival of patients presenting with various stages of epithelial ovarian cancer.
  • MATERIALS AND METHODS: We employed an in-house sandwich enzyme-linked immunosorbent assay method to determine the concentrations of preoperative haptoglobin and C-reactive protein (CRP) in sera samples obtained from 66 malignant tumors, 60 benign tumors, and 10 normal healthy women.
  • RESULTS: Levels of serum haptoglobin significantly correlated with tumor type (P < .001) and International Federation of Gynecology and Obstetrics stage (P < .05).
  • Immunohistochemical findings and Western blot analyses were compatible with sera levels of haptoglobin in which a higher intensity of staining occurred in late-stage epithelial ovarian cancers.
  • CONCLUSION: This study provides evidence that preoperative serum levels of haptoglobin could serve as an independent prognostic factor in patients presenting with epithelial ovarian cancer.
  • [MeSH-major] Haptoglobins / analysis. Neoplasms, Glandular and Epithelial / blood. Ovarian Neoplasms / blood
  • [MeSH-minor] Adult. Aged. C-Reactive Protein / analysis. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Sensitivity and Specificity


82. Cheney RT: The biologic spectrum of thymic epithelial neoplasms: current status and future prospects. J Natl Compr Canc Netw; 2010 Nov;8(11):1322-8
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The biologic spectrum of thymic epithelial neoplasms: current status and future prospects.
  • Thymoma is the most common anterior mediastinal tumor in adults and is frequently associated with autoimmune disorders such as myasthenia gravis.
  • Thymomas are a diverse group of epithelial neoplasms with a behavioral spectrum that spans the complete clinical gamut from entirely benign to highly aggressive, lethal thymic carcinomas.
  • The biologic behavior seems to depend primarily on the clinical stage at presentation and histologic subtype.
  • This article discusses thymic organogenesis, Masaoka staging, WHO histologic classification of thymoma and thymic carcinoma, and selected molecular characteristics that highlight this diversity.
  • This discussion will further underscore both the similarities and differences between categories of thymic epithelial neoplasms and offer support for the notion that tumor heterogeneity and/or tumor progression may explain the observed clinical variation in behavior.
  • Recommendations are offered for future investigational approaches to further the understanding of the complexity of these tumors.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / pathology. Thymus Neoplasms / pathology
  • [MeSH-minor] Humans. Loss of Heterozygosity. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21081787.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Yao J, Chen RJ, Sun XH: [Analysis of the relationship between pathology and recurrence of primary lacrimal epithelial tumors]. Zhonghua Yan Ke Za Zhi; 2006 Jul;42(7):590-3
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the relationship between pathology and recurrence of primary lacrimal epithelial tumors].
  • OBJECTIVE: To analyze the relationship between pathology and recurrence of primary lacrimal epithelial tumors.
  • METHODS: 128 cases of primary lacrimal epithelial tumors including benign mixed tumor (74 cases, 57.8%), adenoid cystic carcinoma (22 cases, 17.2%) and malignant mixed tumor (18 cases, 14.1%) were subjected in the study.
  • RESULTS: The recurrent rate of benign mixed tumor, adenoid cystic carcinoma and malignant mixed tumor was 23.0%, 18.2% and 27.8%, respectively.
  • The recurrence of benign mixed tumor was statistically related to pathological classification and encapsulates.
  • CONCLUSIONS: Primary lacrimal epithelial tumors show variant types and high recurrent rate.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Eye Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology. Neoplasms, Complex and Mixed / pathology
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17081415.001).
  • [ISSN] 0412-4081
  • [Journal-full-title] [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  • [ISO-abbreviation] Zhonghua Yan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


84. Xiang H, Ding W, Liu F, Ren GP, Wang ZM, Zhu XZ: [Clinicopathologic analysis of mixed epithelial and stromal tumor of kidney and adult cystic nephroma]. Zhonghua Bing Li Xue Za Zhi; 2009 Jul;38(7):436-40
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic analysis of mixed epithelial and stromal tumor of kidney and adult cystic nephroma].
  • OBJECTIVE: To study the clinicopathologic features, immunophenotype and differential diagnosis of mixed epithelial and stromal tumor of kidney (MEST) and adult cystic nephroma (CN).
  • One was composed of a mixture of solid and cystic elements, while the remaining case showed a multicystic cut surface bridged by thick fibrous septa.
  • The glandular structures in 2 of the cases were partially lined by endometrial or tubal epithelium.
  • In contrast, the thin-walled cystic spaces in CN were lined by a single layer of epithelium.Immunohistochemical study showed that the epithelial cells were positive for pan-cytokeratin and epithelial membrane antigen.
  • CONCLUSIONS: Both MEST and CN are uncommon renal neoplasm.
  • Most of them run a benign clinical course.
  • [MeSH-major] Epithelial Cells / pathology. Kidney Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781188.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Desmin; 0 / Receptors, Estrogen; 0 / Vimentin
  •  go-up   go-down


85. Kernek KM, Koch MO, Daggy JK, Juliar BE, Cheng L: The presence of benign prostatic glandular tissue at surgical margins does not predict PSA recurrence. J Clin Pathol; 2005 Jul;58(7):725-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of benign prostatic glandular tissue at surgical margins does not predict PSA recurrence.
  • BACKGROUND: Serum prostate specific antigen (PSA) increases after radical prostatectomy are thought to indicate recurrent disease, although some suggest they result from benign prostatic epithelial tissue left at surgical margins.
  • AIMS: To investigate whether presence, location, and extent of benign prostatic tissue at radical prostatectomy surgical margins influence patient outcome.
  • The total length of benign prostatic tissue at the margins, measured for each location using an ocular micrometer, was obtained by summing the length of all positive sites.
  • The presence, anatomical location, and extent of benign prostatic tissue at the margin were correlated with clinicopathological characteristics and postoperative PSA increases.
  • RESULTS: Fifty five cases had benign prostatic glandular tissue at the surgical margin.
  • The most frequent location of benign prostatic tissue was the apex (40 patients).
  • Presence, anatomical location, and length of benign prostatic tissue at the margin were not significantly associated with age, preoperative PSA, prostate weight, pathological stage, tumour volume, largest tumour dimension, Gleason score, extraprostatic extension, seminal vesical invasion, tumour multifocality, perineural invasion, or PSA recurrence.
  • CONCLUSIONS: Benign prostatic tissue was frequently found in margins of apex and bladder base, but uncommon in the anterior or posterior prostate.
  • The presence of benign prostatic tissue at surgical margins had no prognostic relevance.
  • [MeSH-minor] Adult. Age Factors. Aged. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Prognosis. Prostatectomy. Recurrence


86. Zhou JP, Yang ZL, Liu DC, Zhou JP: [Expression of galectin 3 and Sambucus nigra agglutinin and their clinicopathological significance in benign and malignant lesions of stomach]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 May;12(3):297-300
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of galectin 3 and Sambucus nigra agglutinin and their clinicopathological significance in benign and malignant lesions of stomach].
  • OBJECTIVE: To study the expressive levels of galectin-3(gal-3) and Sambucus nigra agglutinin(SNA) and their clinicopathological significance in the benign and malignant lesions of stomach.
  • METHODS: EnVision immunohistochemistry for assaying gal-3 expressive level and ABC cytochemistry for determining SNA expressive level were used in conventional paraffin-embedded sections from specimens of gastric cancer(n=49), peritumoral tissues(n=20), metastatic foci of lymph nodes(n=36), and different types of benign lesions(n=80).
  • RESULTS: The positive rates of gal-3 and SNA were significantly higher in gastric cancer tissues than those in peritumoral tissues and different types of benign lesions(P<0.05, P<0.01).
  • The positive cases of gal-3 and/or SNA in peritumoral tissues and benign lesions showed mild- to severe-atypical hyperplasia of mucous epithelial cells.
  • [MeSH-minor] Adenoma / pathology. Adult. Aged. Female. Gastritis / pathology. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Polyps / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434543.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Galectin 3; 0 / Plant Lectins; 0 / Sambucus nigra lectins; EC 3.2.2.22 / Ribosome Inactivating Proteins
  •  go-up   go-down


87. Akahira J, Suzuki F, Suzuki T, Miura I, Kamogawa N, Miki Y, Ito K, Yaegashi N, Sasano H: Decreased expression of RIZ1 and its clinicopathological significance in epithelial ovarian carcinoma: correlation with epigenetic inactivation by aberrant DNA methylation. Pathol Int; 2007 Nov;57(11):725-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of RIZ1 and its clinicopathological significance in epithelial ovarian carcinoma: correlation with epigenetic inactivation by aberrant DNA methylation.
  • The retinoblastoma protein-interacting zinc finger gene (RIZ1) is considered a tumor suppressor gene.
  • All (6/6) of the normal, 5/9 of benign, and 4/9 of borderline tissues were positive for RIZ1 protein.
  • Decreased expression of RIZ1 was significantly correlated with histological subtypes (P < 0.0001), high tumor grade (P = 0.0153) and advanced clinical stage (P = 0.0345), and high Ki67 index (P = 0.0117) but was not associated with the overall prognoses of the patients (P = 0.519).
  • Reduced expression of RIZ1 may play an important role in the pathogenesis and/or development of epithelial ovarian carcinoma, and is considered to be caused in part by aberrant DNA methylation.
  • [MeSH-minor] Cell Line, Tumor. DNA Methylation. Epigenesis, Genetic. Female. Histone-Lysine N-Methyltransferase. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Promoter Regions, Genetic / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922684.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.1.1.43 / PRDM2 protein, human
  •  go-up   go-down


88. King J, Thatcher N, Pickering C, Hasleton P: Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology; 2006 Dec;49(6):561-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports.
  • AIMS: A systematic review of published reports that have evaluated the ability of immunohistochemistry and argyrophil nucleolar organizing region (AgNOR) staining to distinguish between benign and malignant pleural disease.
  • Desmin and epithelial membrane antigen (EMA) were the most useful, with sensitivity and specificity both above 74%.
  • A high MCM2 labelling index also differentiated between benign and malignant pleural disease.
  • The diagnostic importance of histological features seen on plain tissue sections is emphasized as vital for correctly differentiating between benign pleural disease and malignant pleural mesothelioma.
  • [MeSH-major] Antigens, Neoplasm / immunology. Immunohistochemistry / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Silver Staining
  • [MeSH-minor] Antigens, Nuclear. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Nuclear Proteins. Nucleolus Organizer Region / pathology. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163840.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antigens, Nuclear; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / nucleolar organizer region associated proteins
  • [Number-of-references] 33
  •  go-up   go-down


89. Gopalakrishnan R, Simonton S, Rohrer MD, Koutlas IG: Cystic variant of calcifying epithelial odontogenic tumor. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Dec;102(6):773-7
Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic variant of calcifying epithelial odontogenic tumor.
  • Calcifying epithelial odontogenic tumor (CEOT) is a benign, locally aggressive odontogenic neoplasm characterized by sheets and nests of epithelial cells with deeply eosinophilic or occasionally clear cytoplasm, calcifications, and eosinophilic amorphous material that stains positive for amyloid.
  • [MeSH-major] Maxillary Neoplasms / pathology. Odontogenic Cyst, Calcifying / pathology. Odontogenic Tumors / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17138180.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Downs LS Jr, Lima PH, Bliss RL, Blomquist CH: Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer. J Soc Gynecol Investig; 2005 Oct;12(7):539-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer.
  • OBJECTIVE: Cathepsins B (CB) and D (CD) belong to a family of proteases felt to be important in tumor metastasis and invasion.
  • It has been suggested that both enzymes play a role the progression of epithelial ovarian cancer and they have been investigated as potential biomarkers for ovarian cancer.
  • Tissue specimens were divided into four groups: normal ovary, benign neoplasm, early-stage (I/II) cancer, and late-stage (III/IV) cancer.
  • CONCLUSIONS: CB activity is associated with invasive ovarian neoplasm.
  • [MeSH-minor] Female. Humans. Isoenzymes. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202931.001).
  • [ISSN] 1556-7117
  • [Journal-full-title] Journal of the Society for Gynecologic Investigation
  • [ISO-abbreviation] J. Soc. Gynecol. Investig.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 3.4.22.1 / Cathepsin B; EC 3.4.23.5 / Cathepsin D
  •  go-up   go-down


91. de Moura JP Jr, Nicolau SM, Stávale JN, da Silva Pinhal MA, de Matos LL, Baracat EC, de Lima GR: Heparanase-2 expression in normal ovarian epithelium and in benign and malignant ovarian tumors. Int J Gynecol Cancer; 2009 Dec;19(9):1494-500
SciCrunch. OMIM: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heparanase-2 expression in normal ovarian epithelium and in benign and malignant ovarian tumors.
  • Several papers have associated the expression of heparanase 1 with various malignant tumors.
  • OBJECTIVE: The aim of this study was to evaluate the expression of heparanase 2 in epithelial neoplasia of the ovaries and in samples of normal ovarian tissue.
  • METHODS: Seventy-five ovary specimens were analyzed and divided into 3 groups: 23 malignant and 35 benign epithelial ovarian neoplasia and 17 without ovarian disease.
  • RESULTS: In the quantitative analysis, we found positivity indices for heparanase 2 expression of 72.2% and 87.3% in the samples of benign and malignant neoplasias, respectively.
  • In these, the intensity of expression and the expression index were 147.2 and 121.2, respectively, for the benign neoplasia and 134.1 and 118.0 for the malignant neoplasia.
  • Qualitatively, its expression was strong or moderate in 44.2% of the benign and 78.2% of the malignant tumors; its expression in all of the nonneoplastic samples was negative, with the exception of one that was weakly positive.
  • Furthermore, there was no difference in its expression between benign and malignant ovarian epithelial neoplasia.
  • [MeSH-major] Carcinoma / metabolism. Epithelium / metabolism. Glucuronidase / metabolism. Ovarian Neoplasms / metabolism. Ovary / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Proliferation. Cell Transformation, Neoplastic / metabolism. Disease Progression. Female. Humans. Middle Aged. Neoplasm Staging. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955924.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


92. Tryka E, Skomra D, Klatka J, Gieroba R, Olszański W: [Epithelial cell proliferation in nasal polyps]. Otolaryngol Pol; 2005;59(4):523-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epithelial cell proliferation in nasal polyps].
  • The fact that nasal polyps formation is connected with increase of the epithelial surface suggests that the dysregulation of epithelial cell proliferation takes part in their pathogenesis.
  • Furthermore, macroscopically nonsuspected nasal polyp, usually benign tissue lesion, occasionally may be misdiagnosed such as neoplasm.
  • Only a few studies have undertaken the subject of cell proliferation in nonneoplastic respiratory epithelium.
  • Based on this findings it seems that increased epithelial cell proliferation and chronic inflammation generate the lesion of the nasal mucosa leading to nasal polyps formation.
  • [MeSH-minor] Cell Proliferation. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Inflammation / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273855.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


93. McKenney JK, Soslow RA, Longacre TA: Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol; 2008 May;32(5):645-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
  • Mucinous epithelial neoplasms arising in association with mature teratomas are a heterogeneous group of tumors, but with the exception of a single recent study, their full histologic spectrum, detailed immunophenotype, and association with classic pseudomyxoma peritonei (PMP) have not been fully studied.
  • The morphologic, immunohistochemical, and clinical features of 42 patients with mucinous epithelial tumors arising in association with mature ovarian teratomas were evaluated.
  • Tumor size ranged from 5.5 to greater than 200 cm.
  • Most teratoma-associated mucinous tumors were unilateral, although 1 patient harbored bilateral mucinous tumors in association with bilateral teratomas.
  • Using the 2003 World Health Organization criteria for ovarian intestinal type mucinous neoplasms, 17 (40%) were classified as mucinous cystadenoma, 16 (38%) as intestinal-type mucinous epithelial neoplasm of low malignant potential (IM-LMP), 4 (10%) as intraepithelial carcinoma (IEC), and 5 (12%) as invasive mucinous carcinoma.
  • Mucinous cystadenomas had a varied epithelial lining consisting of lower gastroenteric, gastric foveolar, or müllerian appearance.
  • A CK7+/CK20-phenotype was rare in these later 3 morphologic groups (6%).
  • Pathologic evaluation of the peritoneum in these 12 cases revealed 6 with acellular mucin alone, 3 with low-grade mucinous epithelium (all 3 with ovarian IM-LMP), and 3 with high-grade mucinous carcinomatosis (all 3 with ovarian mucinous adenocarcinoma).
  • We report that a significant proportion of mucinous tumors associated with mature ovarian teratomas present with clinical PMP, which in most cases is associated with IM-LMP.
  • PMP in this setting may harbor microscopic intra-abdominal low-grade mucinous epithelium that is histologically and immunophenotypically similar to that typically seen in appendiceal-related PMP.
  • Pseudomyxoma ovarii is common in this setting, particularly in tumors with IM-LMP histology, but pseudomyxoma ovarii is not predictive of PMP.
  • Ovarian teratoma-associated benign and IM-LMP mucinous neoplasms with microscopic peritoneal low-grade mucinous epithelium do not seem to be at significant risk for intra-abdominal recurrence, but numbers are few and follow-up is limited.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Middle Aged. Mucins / metabolism. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18344868.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


94. Chang T, Husain AN, Colby T, Taxy JB, Welch WR, Cheung OY, Early A, Travis W, Krausz T: Pneumocytic adenomyoepithelioma: a distinctive lung tumor with epithelial, myoepithelial, and pneumocytic differentiation. Am J Surg Pathol; 2007 Apr;31(4):562-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pneumocytic adenomyoepithelioma: a distinctive lung tumor with epithelial, myoepithelial, and pneumocytic differentiation.
  • Pulmonary tumors with epithelial and myoepithelial differentiation are rare, thought to be of bronchial minor salivary gland origin and classified similarly to salivary gland neoplasms.
  • We report a series of a distinctive subtype of pulmonary glandular tumors showing epithelial and myoepithelial differentiation with further pneumocytic specialization.
  • The tumors were grossly circumscribed, 0.8 to 2.6 cm in greatest dimension, and histologically showed glandular and spindle cell differentiation.
  • Some glands were filled with colloidlike secretion and had an inner, cuboidal epithelial cell layer (pankeratin, epithelial membrane antigen, and thyroid transcription factor-1 positive), surrounded by an outer layer of myoepithelial cells merging with foci of spindled myoepithelial cells (high molecular weight keratin, S100, smooth muscle actin, calponin, caldesmon, and p63 positive).
  • There were also some glands lined by a single layer of plump cells that were positive for surfactant protein-A in addition to the other epithelial cell markers.
  • The biologic behavior to date has been benign.
  • This is the first reported series of a distinctive lung tumor with epithelial, myoepithelial, and pneumocytic differentiation that differs histologically from all previously recognized pulmonary salivary gland-type and pneumocytic tumors.
  • It is a unique benign appearing neoplasm for which the designation pneumocytic adenomyoepithelioma is suggested.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Microscopy, Electron, Transmission. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414103.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


95. Agaimy A, Wuensch PH: Perineurioma of the stomach. A rare spindle cell neoplasm that should be distinguished from gastrointestinal stromal tumor. Pathol Res Pract; 2005;201(6):463-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perineurioma of the stomach. A rare spindle cell neoplasm that should be distinguished from gastrointestinal stromal tumor.
  • We report on the first case of benign perineurially differentiated peripheral nerve sheath tumor (perineurioma) presenting as a bleeding gastric mass in a 30-year-old, previously healthy woman with no signs or stigmata of von Recklinghausen's disease or other primary tumor at time of presentation.
  • Gastric resection specimen revealed an ulcerated moderately cellular mesenchymal tumor consisting of elongated wavy spindle cells arranged in a fascicular and sheet-like pattern with focal whorling and occasional alternation of dark staining cellular and light staining hypocellular areas.
  • Tumor cells were strongly immunoreactive for epithelial membrane antigen, CD56 (N-CAM), and vimentin, but were negative for S-100-protein and other lineage-specific epithelial, mesenchymal, hematolymphoid, and reticulo-histiocytic markers.
  • We presume that the combined histological and immunohistochemical profiles of this unusual gastric neoplasm are consistent with a diagnosis of perineurioma with a probably benign biological behavior.
  • To our knowledge, this is the first report of gastric perineurioma, an extremely rare mesenchymal lesion that should be considered among the differential diagnoses of gastrointestinal stromal tumor, especially the so-called KIT-negative GIST.
  • Gastrointestinal perineuriomas might be under-recognized, as our case was initially diagnosed as a benign GIST.
  • [MeSH-minor] Adult. Antigens, CD56 / metabolism. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Mucin-1 / metabolism. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16136753.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Biomarkers, Tumor; 0 / Mucin-1
  •  go-up   go-down


96. Zhong W, Peng J, He H, Wu D, Han Z, Bi X, Dai Q: Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin Invest Med; 2008;31(1):E8-E15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.
  • The purpose of this study is to investigate the expression levels of Ki-67 and PCNA in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) and their potential on the early diagnosis of PCa.
  • METHODS: Human prostate cancer cell lines LNCaP and PC-3, human normal prostate epithelial cell line HuPEC, tissues from patients with PCa (121 cases) and BPH (45) and 36 normal cases were examined for the expression of Ki-67 and PCNA by Reverse Transcription-Polymerase Chain Reaction (RT-PCR).
  • Compared with BPH, the ratio of Ki-67 and PCNA expressed in tumour tissue was increased (P < 0.05).
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Gene Expression Regulation, Neoplastic. Ki-67 Antigen / biosynthesis. Proliferating Cell Nuclear Antigen / biosynthesis. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Cell Line, Tumor. Humans. Male. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction


97. Michal M, Kazakov DV, Síma R, Vanecek T: Primitive small cell tumor with epithelial, gangliocytic, neuroendocrine, and mesenchymal differentiation: report of 2 cases. Int J Surg Pathol; 2007 Oct;15(4):429-36
Genetic Alliance. consumer health - Pancreatic islet cell tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive small cell tumor with epithelial, gangliocytic, neuroendocrine, and mesenchymal differentiation: report of 2 cases.
  • The authors describe 2 tumors that, to the best of their knowledge, are hitherto undescribed.
  • The dark blue cells formed distinct epithelial cords with gland-like formations with mucicarmine-positive mucus.
  • Another distinctive component of the tumors was a mesenchymal one.
  • The mesenchymal areas appeared benign and could be likened to a fibroma having a densely collagenous stroma, or they had spindle cells set in the myxoid background, rendering a myxoma-like appearance.
  • Fluorescence in situ hybridization showed that the tumors are without the EWSR1 gene translocation and gain 12p.
  • We suggest the name "primitive small cell tumor with epithelial, gangliocytic, neuroendocrine, and mesenchymal differentiation" for this neoplasm.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Neuroendocrine Tumors / pathology. Sarcoma, Small Cell / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Aneuploidy. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic. Child, Preschool. Chromosomes, Human, Pair 12. Combined Modality Therapy. Desmosomes / ultrastructure. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Microscopy, Electron, Transmission. Secretory Vesicles / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17913955.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


98. Motamed-Khorasani A, Jurisica I, Letarte M, Shaw PA, Parkes RK, Zhang X, Evangelou A, Rosen B, Murphy KJ, Brown TJ: Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression. Oncogene; 2007 Jan 11;26(2):198-214
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
  • Epidemiological studies have implicated androgens in the etiology and progression of epithelial ovarian cancer.
  • We previously reported that some androgen responses were dysregulated in malignant ovarian epithelial cells relative to control, non-malignant ovarian surface epithelial (OSE) cells.
  • Both cytoplasmic ACHE and BACH2 immunostaining were significantly increased in ovarian cancer relative to benign cases.
  • [MeSH-minor] Acetylcholinesterase / genetics. Acetylcholinesterase / metabolism. Adult. Aged. Aged, 80 and over. Basic-Leucine Zipper Transcription Factors / genetics. Basic-Leucine Zipper Transcription Factors / metabolism. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Cells, Cultured. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Disease Progression. Epithelial Cells / metabolism. Female. Flow Cytometry. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Leucine Zippers. Middle Aged. Oligonucleotide Array Sequence Analysis. RNA, Messenger / analysis. RNA, Messenger / genetics. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Tissue Array Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16832351.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgens; 0 / BACH2 protein, human; 0 / BRCA1 Protein; 0 / Basic-Leucine Zipper Transcription Factors; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.1.1.7 / Acetylcholinesterase
  •  go-up   go-down


99. Cates JM, Byrd RH, Fohn LE, Tatsas AD, Washington MK, Black CC: Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma. Pancreas; 2009 Jan;38(1):e1-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma.
  • OBJECTIVES: Expression of transcription factors that mediate epithelial-mesenchymal transition (EMT), such as Twist and Slug, is correlated with poor prognosis in many tumor types.
  • Selected EMT markers were studied in a series of pancreatic ductal adenocarcinomas (PDAs) and benign pancreatic tissues to determine whether expression levels correlated with diagnosis, histologic grade, or patient outcome.
  • RESULTS: Twist and Slug were identified in both the nucleus and cytoplasm of benign pancreatic ductal epithelium, chronic pancreatitis, and PDA.
  • Compared with normal ductal epithelium, nuclear levels of Twist are decreased in PDA.
  • Epithelial-mesenchymal transition marker expression was not associated with N-cadherin expression, patient outcome, or duration of survival.
  • CONCLUSIONS: Decreased expression of nuclear Twist is observed in malignant pancreatic epithelium.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 May;16(3):251-62 [18301244.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):598-606 [17258791.001]
  • [Cites] J Pathol. 2007 Apr;211(5):507-15 [17299729.001]
  • [Cites] Histopathology. 2007 Apr;50(5):648-58 [17394502.001]
  • [Cites] J Clin Pathol. 2007 May;60(5):510-4 [16822877.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jul 6;358(3):925-30 [17512904.001]
  • [Cites] Pathology. 2007 Jun;39(3):305-18 [17558857.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):816-29 [17243120.001]
  • [Cites] J Surg Res. 2007 Aug;141(2):196-203 [17583745.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4769-76 [17699854.001]
  • [Cites] Gene. 2000 Oct 17;257(1):1-12 [11054563.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1613-8 [11912130.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3241-6 [12082640.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1881-91 [12414534.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):891-8 [12632084.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):740-6 [14644200.001]
  • [Cites] J Histochem Cytochem. 2004 Jul;52(7):959-65 [15208362.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4125-33 [15217949.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 3;85(3):200-6 [8423624.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):188-95 [15644775.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1174-80 [15709186.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):155-65 [15790452.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):488-96 [15864483.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5153-62 [15958559.001]
  • [Cites] Development. 2005 Jul;132(14):3151-61 [15983400.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4524-31 [16002843.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):5991-5; discussion 5995 [16024595.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):5996-6000; discussion 6000-1 [16024596.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):197-209 [16169465.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8070-8 [16299238.001]
  • [Cites] Hum Pathol. 2006 Apr;37(4):431-8 [16564917.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):973-81 [16567498.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3365-9 [16585154.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1816-22 [16773075.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):21321-31 [16707493.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):314-20 [17211477.001]
  • [Cites] Int J Cancer. 2007 Apr 15;120(8):1634-40 [17236203.001]
  • (PMID = 18766116.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / P50 CA095103-10; United States / NCI NIH HHS / CA / P50 CA95103
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CDH2 protein, human; 0 / Cadherins; 0 / Nuclear Proteins; 0 / TWIST1 protein, human; 0 / Transcription Factors; 0 / Twist Transcription Factor; 0 / snail family transcription factors
  • [Other-IDs] NLM/ NIHMS205920; NLM/ PMC2882851
  •  go-up   go-down


100. Koensgen D, Freitag C, Klaman I, Dahl E, Mustea A, Chekerov R, Braicu I, Lichtenegger W, Sehouli J: Expression and localization of e-cadherin in epithelial ovarian cancer. Anticancer Res; 2010 Jul;30(7):2525-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and localization of e-cadherin in epithelial ovarian cancer.
  • MATERIALS AND METHODS: Expression analysis of E-cadherin was performed by immunohistochemistry in 36 patients (12 primary OC, 15 recurrent OC, 9 benign ovarian lesions).
  • Tumor specimens were collected within OC.
  • RESULTS: E-Cadherin was significantly reduced in OC compared to benign ovarian lesions (p=0.024).
  • In primary OC, E-cadherin was comparable in ovarian tumor and corresponding metastatic tumor tissue.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis






Advertisement